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Abstract 
Our research work is divided into three chapters. In the first chapter, synthesis of 
substituted phenolic compounds including halogenated di- and trihydroxybenzenes, 
aminophenols, and substituted di-tert-butylphenols, their redox potential, laccase oxidation, and 
mosquito anti-larval activities are discussed. The synthesized substituted phenols were found to 
be the substrates but not the inhibitors of laccase.  An inverse correlation between the oxidation 
potential and the laccase oxidation efficiency of halogenated hydroxybenzenes and 
aminophenols was established. However, substituted di-tert-butylphenols were found to have 
anti-larval activities in mosquitoes resulting in the death of the larvae just before reaching 
pupation. Among the di-tert-butyl phenols studied, water insoluble, 2,4-di-tert-butyl-6-(3-
methyl-2-butenyl)phenol (16), 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime 
(14), and 6,8-di-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromene (17) caused the mortility of 
98%, 93%, and 92% of Anopheles gambiae larvae in the concentration of 182 nM, 3.4 µM, and 
3.7 µM, respectively. In particular, compound 16 had similar anti-larval activities as compared to 
MON-0585, an anti-larval agent reported by Monsanto in the 70’s.  
In the second chapter, inhibition of protein kinase C (PKC) phosphorylation by 
substituted quinolines (PQs) is inverstigated. PQ compounds such as N-(3-aminopropyl)-6-
methoxy-4-methyl-5-(3-(trifluormethyl)phenoxy)quinolin-8-amine (PQ1), N-(furan-2-ylmethyl)-
6-methoxy-4-methyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine (PQ11), and 6-methoxy-
4-methyl-N-(quinolin-4-ylmethyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine (PQ15) were 
found to inhibit PKC phosphorylation with IC50 values of 35 nM, 42.3 nM, and 216.3 nM 
respectively, among which PQ1 and PQ11 were found to be potent PKC inhibitors as 
comparable to that of staurosporine (IC50 = 33 nM).  
 
 
In chapter three,  the tissue distribution of PQ1 and PQ11 in normal C57BL/6J mice and 
the effect of PQ1 on the normal tissues of mice were investigated. Substituted quinolines, PQ1 
and PQ11 were distributed in the tissues in concentrations that were more than 40 folds of their 
effective dose. PQ1 and PQ11 were also found to penetrate the blood brain barrier and collect in 
the tissue in significant amounts. The administration of PQ1 and PQ11 had no effect in the 
normal behavior of the animals indicating no short term adverse effects. PQ1 was found to 
increase the expression of survivin, an anti-apoptotic factor and decrease the expression of 
cleaved caspase-3 and caspase-8, pro-apoptotic proteins. These studies suggests that PQ1 might 
have anti-apoptotic activities in normal cells, in contrast to the role of PQ1 in cancer cells where 
it has demonstrated to induce apoptosis. The study also indicated that PQ11 was better 
metabolized from the tissues over time as compared to PQ1.  
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Abstract 
Our research work is divided into three chapters. In the first chapter, synthesis of 
substituted phenolic compounds including halogenated di- and trihydroxybenzenes, 
aminophenols, and substituted di-tert-butylphenols, their redox potential, laccase oxidation, and 
mosquito anti-larval activities are discussed. The synthesized substituted phenols were found to 
be the substrates but not the inhibitors of laccase.  An inverse correlation between the oxidation 
potential and the laccase oxidation efficiency of halogenated hydroxybenzenes and 
aminophenols was established. However, substituted di-tert-butylphenols were found to have 
anti-larval activities in mosquitoes resulting in the death of the larvae just before reaching 
pupation. Among the di-tert-butyl phenols studied, water insoluble, 2,4-di-tert-butyl-6-(3-
methyl-2-butenyl)phenol (16), 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime 
(14), and 6,8-di-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromene (17) caused the mortility of 
98%, 93%, and 92% of Anopheles gambiae larvae in the concentration of 182 nM, 3.4 µM, and 
3.7 µM, respectively. In particular, compound 16 had similar anti-larval activities as compared to 
MON-0585, an anti-larval agent reported by Monsanto in the 70’s.  
In the second chapter, inhibition of protein kinase C (PKC) phosphorylation by 
substituted quinolines (PQs) is inverstigated. PQ compounds such as N-(3-aminopropyl)-6-
methoxy-4-methyl-5-(3-(trifluormethyl)phenoxy)quinolin-8-amine (PQ1), N-(furan-2-ylmethyl)-
6-methoxy-4-methyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine (PQ11), and 6-methoxy-
4-methyl-N-(quinolin-4-ylmethyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine (PQ15) were 
found to inhibit PKC phosphorylation with IC50 values of 35 nM, 42.3 nM, and 216.3 nM 
 
 
respectively, among which PQ1 and PQ11 were found to be potent PKC inhibitors as 
comparable to that of staurosporine (IC50 = 33 nM).  
In chapter three,  the tissue distribution of PQ1 and PQ11 in normal C57BL/6J mice and 
the effect of PQ1 on the normal tissues of mice were investigated. Substituted quinolines, PQ1 
and PQ11 were distributed in the tissues in concentrations that were more than 40 folds of their 
effective dose. PQ1 and PQ11 were also found to penetrate the blood brain barrier and collect in 
the tissue in significant amounts. The administration of PQ1 and PQ11 had no effect in the 
normal behavior of the animals indicating no short term adverse effects. PQ1 was found to 
increase the expression of survivin, an anti-apoptotic factor and decrease the expression of 
cleaved caspase-3 and caspase-8, pro-apoptotic proteins. These studies suggests that PQ1 might 
have anti-apoptotic activities in normal cells, in contrast to the role of PQ1 in cancer cells where 
it has demonstrated to induce apoptosis. The study also indicated that PQ11 was better 
metabolized from the tissues over time as compared to PQ1.  
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Chapter 1. Synthesis, redox potential, laccase substrate activity, and 
antilarval activity of substituted phenols 
 
1.1 Introduction 
Laccases (E.C 1.10.3.2) belong to the family of multi copper oxidases along with 
ceruloplasmin (E.C 1.16.3.1) and ascorbate oxidase (E.C 1.10.3.3).
1
 Laccase was first reported 
from the sap of Rhus vernicifera, a Japanese lacquer tree by Yoshida in 1883.
2
 Laccases are 
widely distributed among fungi, higher plants, insects, and bacteria and are known to catalyze 
one electron oxidation of four substrate molecules including substituted o-, m-, and p-phenols, 
polyphenols,  methoxy-phenols, and aromatic amines with subsequent four-electron reduction of 
molecular oxygen to water.
3-7
   
Laccases are known to have diverse physiological functions depending on the organism 
where they are found. Fungi are the largest source of laccases. In fungi, laccases are found to 
play important roles in activities including lignin biodegradation of wood, pigmentation, 
morphogenesis, and plant pathogenesis.
1,8
 In plants, laccases are involved in the synthesis of 
lignin, a component of the plant cell wall and in wound healing.
4,9
 Laccases in bacteria and 
insects are less studied. In bacteria, laccases are believed to participate in the endospore coat 
formation, melanin production, morphogenesis, and detoxification.
10
 In insects, laccases are 
believed to participate in sclerotization and tanning of the new exoskeleton.
11-13
 These diverse 
activities of laccases have attracted attention of a large number of researchers. Since only 
molecular oxygen is required for the catalysis, laccases are useful in many biotechnological 
applications. Presently, laccases find wide range of applications such as wood pulp bleaching 
and delignification in paper industries; detoxification and decontamination of industrial wastes, 
2 
 
pesticides, and herbicides; decolorization of dyes in textile industries; color alternation in food 
and wine industries; medicinal application; and biosensors for phenol or oxygen.
3,14
 
Mosquitoes are the most important vector of human diseases like malaria, dengue, 
encephalitis, etc.
15
 In 2010, about 216 million cases of malaria were estimated with an expected 
deaths of 655,000 worldwide (World Malarial Report, 2011, WHO). Since laccases have not 
been reported in vertebrates but are predicted to play important role in insects’ cuticle 
sclerotization,
11-13
 a vital process in the growth and survival of the insects including mosquitoes,  
insecticides selectively inhibiting laccase would have no adverse effect on vertebrates including 
humans. If laccase substrates upon laccase oxidation produced compound toxic to the mosquito 
larvae either by covalently bonding to the laccase or by targeting other molecular target within 
the insect, they could be developed as a potent pro-insecticides to kill mosquito larvae and help 
in the prevention of mosquito borne diseases like malaria, dengue, etc. Therefore, it is 
noteworthy to synthesize compounds that disrupt cuticle development in insects by selectively 
targeting laccase.   
Since phenolic compounds like catechols are oxidized by laccase during cuticle 
sclerotization or tanning in insects,
16,17
 several halogen substituted phenols and polyphenols, 
amino phenols, and substituted di-tert-butyl phenols were synthesized and their redox potential, 
laccase oxidation activity, and mosquito anti-larval activities were investigated. The synthesized 
substituted phenols are highlighted in Figure 4.  
The redox potentials of these compounds were measured by Thi Nguyen, a graduate 
student in Dr. Hua’s group using the facilities in Dr. Jun Li’s laboratory. The laccase substrate 
activities were measured by Dr. Maureen Gorman and Zeyu Peng in Dr. Michael Kanost 
3 
 
laboratory and the anti-mosquito larval activities were studied in Dr. Kun Yan Zhu’s laboratory. 
All of the above mentioned laboratories are located at Kansas State University. 
  
1.2 Background 
1.2.1 Molecular structure of laccase 
Laccases, blue multi-copper oxidases, in general are extracellular globular glycoproteins 
with molar mass of 60-80 kD and isoelectric point ranging from pH 3.0 to 9.0.
1,18
  In laccase, the 
extent of glycosylation usually ranges between 15 - 20% of the total weight of the protein and is 
related to secretion, activity, copper retention, and thermal stability of the enzyme.
1,19
 The 
protein mainly consists of three domains (D1, D2, and D3) with similar β-barrel type architecture 
as shown in Figure 1.
20,21
  
 
Figure 1: Crystal structure of laccase from Trametes versicolor, elaborated with PyMol from 
crystallographic structure, PDB code 1GYC. 
4 
 
Laccases are commonly found to contain four copper atoms per monomer that include 
one type I, one type II, and two type III coppers bonded to three redox sites designated as T1, T2 
and T3 respectively.
1
 These coppers can be differentiated by UV/Vis and electronic 
paramagnetic resonance (EPR) spectroscopy. In fungal laccase, T1 copper exhibits a planar 
trigonal geometry by coordinating with one cysteine and two histidines residues through sulfur 
and nitrogen atoms respectively.
4
 T1 copper is EPR active and the charge transfer transition from 
the sulfur of cysteine to the T1 copper results in an intense absorbance at around 600 nm giving 
characteristic deep blue color to the enzyme.
4
 T2 copper is also EPR active but does not show 
absorbance in the UV/Vis region, whereas two T3 coppers absorb weakly at 330 nm but are EPR 
silent due to strong antiferromagnetic coupling by a bridging ligand.
4
 One T2 and two T3 copper 
atoms are arranged in a trinuclear cluster and coordinated  to two and six histidines residues, 
respectively (Figure 2).
22
 The T1 copper is the primary electron acceptor site in laccase catalyzed 
reaction, where a single-electron oxidation of a substrate occurs.
22,23
 The electrons from the T1 
copper site are transferred through the highly conserved His-Cys-His tripeptide to the T2/T3 
copper trinuclear cluster, where four-electron reduction of molecular oxygen to water takes 
place.
22,23
 The schematic representation of the oxidation of phenolic substrates and the reduction 
of molecular oxygen to water is highlighted in Figure 2.
6
 
5 
 
 
Figure 2: Schematic representation of oxidation of phenolic substrates and reduction of 
molecular oxygen to water by laccase.
6
 Figure adapted from P. Baldrian, FEMS Microbiol. Rev. 
2006, 30, 215-242 with permission from John Wiley and Sons (copyright © 2005).  
 
1.2.2 Insect laccase in cuticle sclerotization 
Insect cuticles or exoskeleton are extremely diverse materials differing in both physical 
and chemical properties, and play important roles in several activities including protection 
against the environment, excretion, locomotion, and respiration.
24
 In cuticular sclerotization, N-
acylcatecholamines in the procuticle are oxidized to o-quinones or p-quinone methides by 
laccase and/or tyrosinase followed by the Michael addition of nucleophilic side chain function of 
histidines and other amino acids of cuticular proteins to form covalently bonded cross-linked 
adduct as shown in Figure 3.
12
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Figure 3: Proposed protein cross-linking during cuticle sclerotization in pupa of Manduca 
sexta.
12
 Figure adapted Karmer et al. Tetrahedron 2001, 57, 385-392 with permission from 
Elsevier (copyright © 2001). 
  
Tyrosinase, a monophenol monooxygenase, is able to hydroxylase monophenols to o-
diphenols and further oxidize them to its corresponding o-quinones but is unable to oxidize p-
dihydroquinones.
25
 Whereas, laccase cannot hydroxylase monophenols to diphenols but can 
oxidize both o-diphenols and p-dihydroquinones to their corresponding quinones.
25
 Among 
tyrosinase and laccase which enzyme plays a vital role in cuticle sclerotization was a matter of 
debate until 2005, when Arakane et al. demonstrated that laccase 2 but not tyrosinase was 
important in the cuticle sclerotization and pigmentation in red flour beetle, Tribolium 
castaneum.
13
 For this, RNA interference experiments were carried out to lower the levels of 
laccase or tyrosinase in the insects. Insects injected with dsRNA for laccase 2 gene (decreases 
the level of laccase 2) failed to tan normally and died subsequently, whereas insects injected with 
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dsRNAs for tyrosinsase gene had no effect on cuticle tanning.
13
 The leading role of laccase in 
cuticle sclerotization as compared to tyrosinase was further supported by the design of an in vitro 
sclerotization reaction, in which N-acylcatecholamines, compounds known to take part in cuticle 
sclerotization, were incubated with recombinant cuticular proteins MsCP36 derived from the 
tobacco hornworm, Manduca sexta in the presence of laccase and tyrosinase separately.
26
 
Reaction of MsCP36 with N-β-alanyldopamine (NABD) and laccase produced cross-linked 
oligomers and polymers immediately, whereas such cross-linking was not observed in the 
absence of either NABD or laccase. Substituting laccase with tyrosinase and performing reaction 
under similar conditions also gave cross-linked products but in lesser extent and the cross-linked 
product consisted largely of oligomers; no polymers formation was detected.
26
  
 
1.2.3 Laccase inhibitors 
Laccase inhibitors are rare and limited to few inorganic and organic compounds.
27,28
 
Small inorganic anions such as the azide, halides, cyanide, and hydroxide have shown to inhibit 
laccase activity by binding to the T2 and T3 copper atoms disrupting the electron transfer 
process.
29,30
 Some other laccase inhibitors include sulfhydryl compounds, hydroxyglycine, kojic 
acid, and cationic quaternary ammonium detergents.
18,27,31
  
 
1.3 Synthesis  
With an objective to synthesize laccase inhibitors several halogen substituted phenols and 
polyphenols, methoxy-phenols, amino phenols, and substituted di-tert-butyl phenols were 
synthesized (Figure 4).  
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The synthesis of halogenated phenols (compound 1 – 6) was based on the idea that: upon 
laccase oxidation the halogenated phenol would produce reactive cyclic haloenone, which might 
undergo substitution of halogen moiety by the nucleophilic function such as amino group of 
lysine or hydroxyl group of serine or tyrosine of laccase resulting in the formation of covalently 
linked adduct. This covalent linkage might lead to the irreversible inhibition of laccase and 
disrupt the cuticle sclerotization process in mosquitoes causing their death.  
 
Scheme 1: a) Proposed laccase oxidation of p-dihydroquinone 2 to p-quinone 19 and b) Reaction 
of p-quinone 19 with L-alanine benzyl ester 20 to form a covalently linked adduct 21 
 
 
 
As expected, p-quinone 19, compound that would form by the laccase oxidation of p-
hydroquinone 2, was found to undergo nucleophilic addition-elimination reaction to produce 
substituted product 21 on treatment with L-alanine benzyl ester p-toluenesulfonic acid salt 20 
and two equivalents of triethylamine in dichloromethane at 25
o
C (Scheme 1). The amino 
function of L-alanine benzyl ester 20 mimics the amino function of lysine residue of laccase. 
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Synthesized diphenols: 2, 4, and 5 are positional isomers having the hydroxyl groups oriented 
towards para, ortho, and meta positions, respectively. Since the ease of oxidation of diphenols is 
para (dihydroquinone) > ortho (catechol) > meta (resorcinol),
32,33
 compound 4 (o-diol) would 
show lesser activity than compound 2 (p-diol) towards laccase oxidation and produce o-quinone. 
Compound 3 (o-diol) also would produce o-quinone upon laccase oxidation and is expected to 
have similar laccase activity as compared to compound 4. Among the diphenols, compound 5 
(m-diol) would show lower laccase oxidation activity as compared to its ortho and meta isomers. 
Compound 1, on laccase oxidation would produce hydroxymethine quinone and should possess 
similar laccase oxidation activity as compared to compound 2. Compound 6 (triol) having both 
ortho and para oriented hydroxyl groups would have the highest laccase activity among the 
synthesized halogen substituted phenols. The introduction of methoxy group in phenolic 
compounds has been found to increase their laccase oxidation activity;
34
 therefore, the presence 
of methoxy group in compounds 1, 2, 4, and 5 should enhance their laccase oxidation activity.  
Moreover, the amino function of synthesized o-aminophenols 7
35
 and 8
36
 might strongly 
bind to the T1 copper of laccase and upon laccase oxidation would produce more reactive 
iminoquinone. The nucleophilic moieties like amino or hydroxyl function present in the laccase 
protein close to the T1 copper site might add irreversibly to the iminoquinone producing a 
covalently linked adduct and inhibit laccase activity.
37,38
  
 MON-0585, 2,6-di-tert-butyl-4-(α,α-dimethylbenzyl)phenol), developed by Monsanto 
Co. in the 70’s, is a juvenile hormone mimic and found to inhibit cuticle sclerotization in 
mosquitoes.
39
 Moreover, 2,6-di-tert-butyl phenols are oxidized by Co(II)-Schiff base complex 
and oxygen to give 4-substituted 2,6-di-tert-butyl-6-hydroperoxy-2,4-cyclohexadienones.
40,41
 
Therefore, various substituted di-tert-butyl phenols 10 – 16 were synthesized as shown in Figure 
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4. Compound 17 was derived as a byproduct during the synthesis of compound 16. These 4-
substituted di-tert-butyl phenols may undergo oxidation in the presence of copper and oxygen in 
the active site of laccase resulting in the formation of phenoxy radicals or corresponding 
cyclohexadienone disrupting cuticle sclerotization in mosquitoes. As compared to MON-0585, 
2,6-di-tert-butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol 11 has an additional primary alcohol 
group which might lead to its binding with laccase. Furthermore, the alcohol function in 
compound 11 could be transformed to various functional groups such as aldehyde in compound 
12, carboxylic acid in compound 13, oxime in compound 14, and amine in compound 15.  The 
presence of additional functional group such as  -OH, -CHO, -COOH, -N=OH, and -NHR  in 
compounds 11 - 15 as compared to MON-0585 might increase their binding with laccase 
resulting in the effective disruption of cuticle sclerotization in mosquitoes.  
Hence, in this chapter, various halogen substituted phenols and polyphenols, 
aminophenols, and di-tert-butyl phenols were synthesized and their redox potentials, laccase 
substrate activities, and mosquito anti-larval activities were studied. Synthesis of compound 1 
has been previously reported by Dr. Hua’s laboratory,42 and Compound 13 and 21 were 
synthesized by Thi Nguyen, a graduate student in Dr. Hua’s laboratory.43 
11 
 
 
 
Figure 4: Synthesized halogen substituted phenols and polyphenols, aminophenols, and di-tert-
butyl substituted phenols. 
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1.3.1 Synthesis of halogen substituted phenols and polyphenols 
1.3.1.1 Synthesis of compound 2   
2-Bromo-3-chloro-5-methoxy-1,4-dihydroxybenzene (compound 2) was synthesized 
from its precursor 3-chloro-4-hydroxy-5-methoxybenzaldehyde (1), an intermediate previously 
reported by Hua’s lab in the synthesis of (+)-chloropuupehenone,42 following a sequence of 
reactions as outlined in Scheme 2.  
 
Scheme 2: Synthesis of compound 2 
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The free hydroxyl function of 3-chloro-4-hydroxy-5-methoxybenzaldehyde (1) was 
protected as silyl ether by the use of tert-butyldimethylsilyl chloride in the presence of 
triethylamine and 4-dimethylaminopyridine (DMAP) in dichloromethane at 25
o
C for 12 hours to 
give 4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxybenzaldehyde (22) in 85% yield. Baeyer-
Villiger oxidation of compound 22 with the use of m-chloroperbenzoic acid (MCPBA) in 
dichloromethane under reflux for 8 hours gave 4-(tert-butyldimethylsilyloxy-3-chloro-5-
methoxyphenyl formate (23) along with the hydrolyzed product 4-(tert-butyldimethylsilyloxy)-3-
chloro-5-methoxyphenol (24) in the yield of 63% and 27%, respectively. The formate function of 
compound 23 was hydrolyzed to the phenolic function by basic methanolysis using potassium 
carbonate (K2CO3) in methanol at 25
o
C for 4 hours to give phenol 24 in 90% yield. The less 
hindered C-2 position in compound 24 was regioselectively brominated by the use of N-
bromosuccinimide (NBS) in dimethylformamide (DMF) at room temperature for 12 hours 
following the literature published by Hua’s group in the total synthesis of (+)-
chloropuupehenone.
42
 However, bromination of compound 24 under NBS condition gave 2-
bromo-3-chloro-5-methoxy-1,4-benzoquinone (19) along with the desilylated product 2-bromo-
4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (25) in 48% and 31% yield, 
respectively.  Compound 19 might have formed by the hydrolytic cleavage of silyl ether 25 by 
the HBr generated from the action of NBS and trace amount of water in the reaction mixture 
followed by the oxidation to the quinone. NBS oxidation of dihydroquinone to benzoquinone has 
been previously reported by Barakat et al.
44
 Interestingly, disilylation of compound 25 by the use 
of tetra-n-butylammonium fluoride (TBAF) in THF at 0
o
C for 30 minutes gave quinone 19 in 
81% yield.  Reduction of compound 19 in presence of 10% palladium/carbon in ethanol under 
hydrogen (1 atm.) at 25
o
C for 15 minutes afforded the desired compound 2-bromo-3-chloro-5-
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methoxy-1,4-dihydroxybenzene (2) in 100% yield. Infrared spectra of compound 19 does not 
shown a characteristic hydroxyl stretch but shows a quinone stretch at 1683 cm
-1
, whereas 
compound 2 shows hydroxyl absorption at 3303 cm
-1
 implying compounds 19 and 2 are quinone 
and dihydroquinone, respectively.  
  
1.3.1.2 Synthesis of compound 3 and 4   
 The synthetic route of 3-chloro-4,5-dihydroxybenzaldehyde (3) and 4-bromo-3-chloro-5-
methoxybenzene-1,2-diol (4) is outlined in Scheme 3. Compound 3, and 26 – 29 were 
synthesized from 3-chlorovanillin (1) following the literature previously reported by Hua’s lab.42  
 
Scheme 3: Synthesis of compound 3 and 4 
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  Compound 3 was obtained in 86% yield by demethylation of 3-chlorovanillin (1) with 
boron tribromide (BBr3) in CH2Cl2 at 0
o
C for 30 minutes and 25
o
C for 12 hours. The two 
hydroxyl functions on C-4 and C-5 position of compound 3 were then protected by the use of 
tert-butyldimethylsilyl chloride, triethylamine, and 4-dimethylaminopyridinene (DMAP) in 
CH2Cl2 at 0
o
C for 1 hour and 25
o
C for 3 hours to give 3,4-bis(tert-butyldimethylsilyloxy)-5-
chlorobenzaldehyde (26) in 79% yield. Compound 26 on Baeyer-Villiger oxidation using 
MCPBA (70% pure) in CH2Cl2 under reflux for 10 hours afforded 3,4-bis(tert-
butyldimethylsilyloxy)-5-chlorophenyl formate (27) in 79% yield. Basic methanolysis of formate 
27 was carried out with K2CO3 in methanol at 25
o
C for 12 hours to give 3,4-bis(tert-
butyldimethylsilyloxy)-5-chlorophenol (28) in 87% yield. The less hindered C-2 position of 
compound 28 was regioselectively brominated by the use of NBS in DMF for 22 hours to give  
2-bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-chlorophenol (29) in 63% yield; based on the 
recovery of the starting material. Methylation of the phenolic hydroxyl moiety in compound 29 
was achieved by the use of trimethyloxonium tetrafluoroborate (Me3O•BF4) in the presence of 
proton sponge in CH2Cl2 at 0
o
C for 8 hours to give 2-bromo-4,5-bis-(tert-butyldimethylsilyloxy)-
3-chloro-1-methoxybenzene (30) in 95% yield. Finally, the desired compound, 4-bromo-3-
chloro-5-methoxybenzene-1,2-diol  (4) was obtained by the desilylation of compound 30 with  
TBAF in THF at 0
o
C for 30 minutes in 71% yield.  
 Under TBAF reaction conditions compound 4 does not undergo oxidation to give the 
corresponding o-quinone as that of p-dihydroxybenzene 2 which is evident from IR spectrum 
showing strong hydroxyl absorptions at 3436 cm
-1
 and 3219 cm
-1
. 
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1.3.1.3 Synthesis of compound 5 
 The synthesis of 4-bromo-5-chloro-6-methoxybenzene-1,3-diol (5) is outlined in Scheme 
4. Selective protection of hydroxyl moiety on C-5 position of compound 3 was achieved by the 
use of equivalent amount of tert-butyldimethylsilyl chloride in the presence of triethylamine and 
4-dimethylaminopyridine (DMAP) in dichloromethane at 25
o
C for 8 h to give 3-(tert-
butyldimethylsilyloxy)-5-chloro-4-hydroxybenzaldehyde (31) and compound 26 (with both 
protected hydroxyl groups) in 70% and 11% yield, respectively. The structure of compound 31 
was confirmed by single-crystal X-ray analysis as shown in Figure 5. The less hindered C-5 
hydroxyl moiety in compound 3 is likely to react faster with tert-butyldimethylsilyl chloride than 
the more hindered C-4 hydroxyl moiety giving compound 31 predominantly. Methylation of the 
phenolic hydroxyl moiety in compound 31 was achieved by the treatment with trimethyloxonium 
tetrafluoroborate and proton sponge in dichloromethane at 0
o
C for 8 hours to give 3-(tert-
butyldimethylsilyloxy)-5-chloro-4-methoxybenzaldehyde (32) in 78% yield; based on the 
recovery of starting material 31. Compound 32 on Baeyer-Villiger oxidation by the use of 
MCPBA (70% pure) in CH2Cl2 under reflux for 12 hours afforded 3,4-bis(tert-
butyldimethylsilyloxy)-5-chloro-4-methoxyphenyl formate (33) along with the hydrolyzed 
product 3-(tert-butyldimethylsilyloxy)-5-chloro-4-methoxyphenol (34)  in 42%  and 44% yield, 
respectively. Basic methanolysis of the formate function in compound 33 with potassium 
carbonate (K2CO3) in methanol at 25
o
C for 12 hours afforded phenol 34 in quantitative yield. 
Regioselective bromination on the less hindered C-2 position of compound 34 was achieved by 
the use of NBS in DMF for 12 hours giving 2-bromo-5-(tert-butyldimethylsilyloxy)-3-chloro-4-
methoxyphenol (35) in 67% yield. Finally, desilylation of compound 35 by treating with TBAF 
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in THF at 0
o
C for 30 minutes led to the formation of desired product 4-bromo-5-chloro-6-
methoxybenzene-1,3-diol (5) in 60% yield. 
 
Scheme 4: Synthesis of compound 5 
 
   
18 
 
 
Figure 5: Crystal structure of compound 31. 
  
1.3.1.4 Synthesis of compound 6 
5-Bromo-6-chlorobenzene-1,2,4-triol (6) was synthesized from 4-bromo-3-chloro-1,2-
dibenzyloxy-5-(tert-butyldimethylsiloxy)benzene (36), an intermediate previously reported by 
Hua’s lab in the synthesis of (+)-chloropuupehenone,42 in two steps as outlined in Scheme 5.  
 
Scheme 5: Synthesis of compound 6 
 
 
Desilylation of 4-bromo-3-chloro-1,2-dibenzyloxy-5-(tert-butyldimethylsiloxy) benzene 
(36) by the use of TBAF in THF at 0
o
C for 1 hour afforded 2-bromo-3-chloro-4,5-
dibenzyloxyphenol (37) in 74% yield. Finally, removal of two benzyl groups in compound 37 by 
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catalytic hydrogenation (H2, 1 atm.) in the presence of 10% palladium/carbon in ethanol at 25
o
C 
for 3 hours gave 5-bromo-6-chlorobenzene-1,2,4-triol (6) as the desired product in 93 % yield. 
The infrared spectrum of triol 6 shows strong hydroxyl absorption at 3382 cm
-1
. Triol 6 on 
standing in air produced a black solid which might have resulted from its air oxidation to 
quinone followed by decomposition.  Hence, triol 6 was immediately stored in a dry box under 
nitrogen atmosphere. 
  
 1.3.2 Synthesis of aminophenols 7 and 8 
 A reaction for the selective reduction of the nitro function in 4-hydroxy-3-
nitrobenzaldehyde (38) by the use of iron in the presence of acetic acid led to the formation of 
mixture of several compounds, as indicated by TLC analysis, which could not be separated and 
analyzed. However, catalytic hydrogenation of 4-hydroxy-3-nitrobenzaldehyde by the use of 
catalytic amount of palladium/carbon under 30 psi of hydrogen in ethanol for 4 hours gave 2-
amino-4-(hydroxymethyl)phenol (7)
35
 and 2-amino-4-methylphenol (8)
36
 each with 41% yield as 
shown in Scheme 6.  The products were formed by the reduction of both nitro and aldehyde 
functions of 4-hydroxy-3-nitrobenzaldehyde. Compound 8 is formed by the further reduction of 
benzylic hydroxyl function in compound 7 under hydrogenation condition. No reaction was 
observed when the catalytic hydrogenation was carried out in the presence of Raney Nickel 
under similar reaction conditions. On reducing the pressure of hydrogen to 1 atmosphere and 
time to one hour, compound 7 and 8 were obtained in 24% and 61% yield, respectively.  
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Scheme 6: Synthesis of compound 7 and 8 
 
 
 
1.3.3 Synthesis of di-tert-butyl phenols 
 1.3.3.1 Synthesis of compounds 9 - 15 
MON-0585 (18) is a juvenile hormone mimic and implicated as insect growth 
regulators.
45
 MON-0585 is also known to affect cuticle sclerotization in mosquitoes.
39
 In search 
of new anti-larval agents, several 2,6-di-tert-butyl phenols 9 – 15 were synthesized mimicking 
the structure of  MON-0585 as outlined in Scheme 7.  
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Scheme 7: Synthesis of compound 9 - 15 
 
 
Following the reported procedure,
46
 Friedel-Craft acylation of 2,6-di-tert-butylphenol 
(39) with isobutyryl chloride (40) in the presence anhydrous aluminum chloride (AlCl3) at -10
o
C 
for 15 minutes gave compound 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (9) 
in 90% yield. Bromination of compound 9 with cupric bromide in a solvent mixture of 
dichloromethane and ethyl acetate for 3 h afforded 2-bromo-1-(3,5-di-tert-butyl-4-
hydroxyphenyl)-2-methylpropan-1-one (10) in 96% yield which on further treatment with excess 
of lithium aluminum hydride (LiAlH4) in dry diethyl ether under reflux for 3 h gave 2,6-di-tert-
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butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol (11)
47
 in 100% yield.
47
 Compound 11 is likely 
formed by the hydride attack on the carbonyl carbon followed by aryl group rearrangement.
47
 
Compound 11 on oxidation with o-iodoxybenzoic acid (IBX) in dimethyl sulfoxide (DMSO) for 
12 hours furnished 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal (12) in 99% yield. 
Aldehyde 12 was further oxidized to 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanoic 
acid (13)
41
 in 82% yield by treating with silver oxide, prepared in situ by reacting silver nitrate 
(AgNO3) and sodium hydroxide (NaOH) in the solvent mixture of water and 1,4-dioxane at 25
o
C 
for 12 hours. Treatment of aldehyde 12 with hydroxylamine hydrochloride and sodium acetate in 
a solvent mixture of acetonitrile and water (2:1) for 1.5 hour gave (E)-2-(3,5-di-tert-butyl-4-
hydroxyphenyl)-2-methylpropanal oxime (14) in 97% yield. The oxime 14 could not be reduced 
to its corresponding amine on catalytic hydrogenation by the use of 10 % palladium/carbon in 
ethanol under 30 psi of hydrogen for 16 hours. Reductive amination of aldehyde 12 by the use of 
benzylamine in toluene under reflux condition for 12 hours followed by the removal of toluene 
under rotovapor and addition of methanol and sodium cyanoborohydride (NaBH3CN) gave 4-(1-
(benzylamino)-2-methylpropan-2-yl)-2,6-di-tert-butylphenol (15) in 97% yield. The removal of 
benzyl group in compound 15 to give its corresponding amine was not achieved under catalytic 
hydrogenation condition by the use of hydrogen (30 psi) in the presence of 10% 
palladium/carbon in ethanol for 12 hours. Moreover, increasing the temperature to 50
o
C had no 
effect on the reaction and resulted in the recovery of the starting material. Changing the catalyst 
to platinum oxide (PtO2) also failed in the removal of benzyl group.  The reaction might have 
failed due to the poisoning of the catalyst by the trace amount of the product formed.  
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1.3.3.2 Synthesis of compound 16, 17 and MON-0585 (18) 
In addition to the 2,6-di-tert-butyl phenolic compounds as highlighted in Scheme 7, 
synthesis of 2,4-di-tert-butyl-6-(2-methylbut-3-en-2-yl)phenol (43) was envisioned by following 
Friedel-Crafts alkylation of 2,4-di-tert-butyl phenol (41) and 2-methyl-3-buten-2-ol (42) as 
highlighted in Scheme 8. Compound 43 would have all the major structural features of MON-
0585; moreover, would have an additional side chain with a terminal double bond that could be 
manipulated into different functional groups as required. However, instead of giving  compound 
43, treatment of 2,4-di-tert-butyl phenol with 2-methyl-3-buten-2-ol in the presence of 
borontrifluoro etherate (BF3•O(Et)2) in dichloromethane at 25
o
C for 1 hour afforded 2,4-di-tert-
butyl-6-(3-methyl-2-butenyl)phenol (16) and 6,8-di-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-
chromene (17) in 46% and 10% yield respectively (Scheme 8a). Benzopyran 17 appears to be 
derived from an acid-catalyzed ring closing reaction of compound 16 as highlighted in Scheme 
8b. 
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Scheme 8: a) Synthesis of compound 16 and 17 and b) proposed mechanism for the formation of 
16 and 17 
 
 
 
Similarly, 2,6-di-tert-butyl-4-cumylphenol (18) was prepared by a Friedel-Crafts 
alkylation reaction of 4-cumylphenol (44) and isobutylene (45) in the presence of catalytic 
amount of sulfuric acid in dichloroethane in a sealed tube at 80
o
C for 6 h as shown in Scheme 9.  
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Scheme 9: Synthesis of MON-0585 
 
 
1.4 Results and discussions 
Laccases are predicted to be vital in the cuticle tanning or sclerotization in insects.
13
 The 
redox potential of the T1 copper is found to vary from 430 mV to 780 mV depending on the type 
of laccases.
48
 Moreover, the oxidation of phenols by laccases depends on the redox potential 
difference between the phenolic compound and the T1 copper, and in many cases the higher the 
redox potential of T1 copper (or lower the redox potential of the substrates) the higher is the 
catalytic efficiency of laccases towards the substrates.
30
 In other words, the laccase catalytic 
efficiency is inversely correlated with the oxidation potential of substrates.
18
 To determine the 
activity of the synthesized compounds towards laccase, redox potential and laccase substrate 
activities of these compounds were determined. Inverse correlations between the oxidation 
potentials and the laccase oxidation efficiency of these compounds was also established.
43
   
The redox potentials of these compounds were measured by Thi Nguyen, a graduate 
student in Dr. Hua’s group using the facilities in Dr. Jun Li’s laboratory. The laccase activities 
were measured by Dr. Maureen Gorman and Zeyu Peng in Dr. Michael Kanost laboratory and 
the mosquito anti-larval activities were studied in Dr. Kun Yan Zhu’s laboratory. 
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Synthesized compounds 1 – 8 along with two commercially available compounds 3-
amino-4-hydroxybenzoic acid (46) and 4-amino-3-hydroxybenzoic acid (47) were tested for 
irreversible inhibition of fungal laccase in Dr. Michael Kanost laboratory by Dr. Maureen 
Gorman and were found to be the substrates but not the inhibitors of laccase. 
 
1.4.1 Redox potentials and laccase substrate oxidation studies 
Cyclic voltammetry (CV) experiments were carried out to study the redox properties of 
compounds 1 - 8, 10 - 17, MON-0585 (18), 46, 47 including other known laccase substrates like 
hydroquinone, catechol, 2-aminophenol, 1,2-phenylenediamine,  and 2,2’-azino-bis-(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS).  The known laccase substrates were used as 
positive control in the experiment. The CV measurements were obtained by Thi Nguyen, a 
graduate student in Dr. Hua’s lab and has been published;43 therefore, only the summary of the 
result will be highlighted here.  
Most of the compounds with the exception to compounds 11 - 13, 16, 17 and 21 showed 
redox properties (redox potential values) as indicated by the presence of both oxidation and 
reduction peaks in their cyclic voltammogram. Interestingly, the redox potentials for the 
synthesized compounds were found in the range of 10 mV to 340 mV; generally lower than the 
redox potential of T1 copper site in laccases.
48
 Under identical condition, the redox potential of 
the known laccase substrates like hydroquinone, catechol, 2-aminophenol, 1,2-
phenylenediamine, and ABTS were measured as 198 mV, 310 mV, 245 mV, 225mV, and 570 
mV, respectively. Therefore, the synthesized compounds having lower or similar redox 
potentials as that of the known laccase substrates could be easily oxidized by laccase. As 
expected, p-diphenols 2 and 6 (triol) had lower redox potential of 95 mV and 45 mV respectively 
27 
 
as compared to the o-diphenols 3 and 4 with 265 mV and 185 mV respectively. Furthermore, the 
m-diphenol 5 was found to have the highest redox potential of 340 mV among the polyphenols. 
These results are in agreement with the oxidation order of p-diphenols> o-diphenols> m-
diphenols.
32
 Comparing the redox potentials of hydroquinone (198 mV) to compound 1 (95 mV) 
and catechol (310 mV) to compound 4 (185 mV), it is found that the introduction of electron 
donating methoxy group in phenolic compound increase their oxidation tendency; which is 
consistent to previous study.
34
 Aminophenols 7 and 8 were found to have redox potential of 165 
mV and 210 mV respectively and also would be easily oxidized by laccase.  However, 
substituted di-tert-butyl phenolic compound 10 - 16, benzopyran 17, and MON-0585 (18) caused 
unreliable CV measurements due to their lower solubility in the aqueous PBS buffer solution 
containing 20% of ethanol. These compounds either showed higher redox potentials (> 530 mV) 
or failed to show oxidation or reduction wave within the experimental range of + 0.8 to 1.2 V.  
Since the redox potential values of water soluble compounds 1 – 8 indicated that they 
could be easily oxidized by laccase, the laccase oxidation activity of these compounds along with 
known laccase substrates such as hydroquinone, catechol, 2-aminophenol, 1,2-
diphenyleneaminem and ABTS were studied with fungal laccase Trametes versicolor.
49
 The 
known laccase substrates were used as positive control and for comparison. Due to the water 
insolubility of substituted di-tert-butyl phenolic compounds 10 - 16, benzopyran 17, and MON-
0585 (18), they were not oxidized by laccase. Laccase oxidation studies of these compounds 
were carried by Dr. Maureen Gorman and Zeyu Peng in Dr. Michael Kanost laboratory and the 
result has been published;
43
 therefore, only the summary of the result is highlighted here.  
The laccase oxidation efficiency (kcat/Km) for the known laccase substrates: 
hydroquinone, catechol, 2-aminophenol, 1-2-phenylenediamine, and ABTS against fungal 
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laccase, Trametes versicolor were measured as 35650, 3350, 11840, 2420, and 92890 min
-1
mM
-1
 
respectively. Compound 6, a triol having both ortho- and para-substituted phenolic moieties had 
the highest laccase oxidation efficiency of 173600 min
-1
mM
-1
. Though, compound 1, a p-
diphenol had lower laccase oxidation efficiency (15710 min
-1
mM
-1
) than p-hydroquinone, but 
still was a better laccase substrate as compared to catechol (o-diphenol) and 2-aminophenol.   
Moreover, the o-diphenol 4 was found to be better laccase substrate than m-diphenol 5 as 
indicated by their kcat/Km values of 134500 and 82290 min
-1
mM
-1
, respectively. Comparing the 
laccase oxidation efficiency of compound 1 (2-methoxy substituted phenol; kcat/Km = 2870 min
-
1
mM
-1
) with compound 3 (1,2-diol; kcat/Km = 47500 min
-1
mM
-1
) and compound 4 (4-methoxy 
substituted 1,2-diol; kcat/Km = 134500 min
-1
mM
-1
) with compound 6 (1,2,4-triol; kcat/Km = 
173600 min
-1
mM
-1
), indicated that the substitution of methoxy group by hydroxyl group in the 
phenolic compound increases the laccase oxidation efficiency of the compound. The result also 
indicated that; higher the number of hydroxyl group in the substrate, greater is the laccase 
oxidation efficiency of the compound. Moreover, the laccase oxidation efficiency of compound 4 
was greater than that of compound 5 indicating that o-diphenols are better laccase substrates than 
m-diphenols. Aminophenols 7 and 8 had kcat/Km values of 71550 and 47250 min
-1
mM
-1
 
respectively indicating that they are better oxidized by laccase than 2-aminophenol, a known 
laccase substrate. However, among the known laccase substrates studied, ABTS was only found 
to have comparable laccase oxidation efficiency as that of the synthesized polyphenols and 
aminophenols. In summary, the laccase oxidation efficiency of most of the synthesized 
polyphenols and aminophenos were found to be higher than that of the known laccase substrates 
including hydroquinone, catechol, 2-aminophenol, and 1,2-phenylenediamine indicating their 
role as better laccase substrates.  
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The redox potential and laccase oxidation efficiency of the compound studied could not 
be correlated; however, the inverse correlation between the oxidation potential and the laccase 
oxidation efficiency of the studied compounds including hydroquinone, catechol, 2-
aminophenols, 1,2-phenylenediamine, ABTS, compounds 1 - 8, 34, and 35 was established and 
is highlighted in Figure 6. For example, compound 6 with the lowest oxidation potential (80 mV) 
was found to have the highest laccase oxidation efficiency. On other hand, compound 1 with the 
highest oxidation potential (670 mV) was found to have the lowest laccase oxidation efficiency.  
 
 
Figure 6: Inverse correlation between the laccase oxidation efficiency and oxidation potential of 
Compounds 1 – 8, 46, 47, ABTS, 2-aminophenol, catechol, hydroquinone, and 1,2-
phenylenediamine.
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 Figure adapted from Prasain et al. Bioorganic & Medicinal Chemistry 2012, 
20, 1679-1689 with permission from Elsevier (copyright © 2012). 
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1.4.2 Anti-mosquito larval activities 
The phenolic substrates oxidized by laccase are used as the building blocks in the insect 
cuticle sclerotization,
16,17
 and MON0585, a substituted di-tert-butyl phenolic compound is 
known to disrupt the cuticle sclerotization in insects.
39
 Therefore, mosquito anti-larval activities 
of laccase substrates such as triol 6 and dihydroquinone, and various di-tert-butyl phenolic 
compounds including compound 10 - 16, MON-0585 (18), and di-tert-butyl substituted 
benzopyran 17 were investigated in the third-instar larvae of Anopheles gambiae in a three-day 
bioassay. MON-0585 was used as control and for comparison. This study was performed in Dr. 
Kun Yan Zhu laboratory and the result has been published;
43
 therefore, only the results are 
summarized here.  
For the anti-larval assay, water soluble compounds like hydroquinone and triol 6 were 
dissolved in water and used; whereas di-tert-butyl phenol derivatives 10 - 16 and benzopyran 17 
were first dissolved in acetone and used for the assay in aqueous solution. The toxicity studies 
were investigated for two concentrations for each compound; 50 and 1000 µg/mL.  
Compound 6 and dihydroquinone, water soluble laccase substrates, were not toxic to the 
larvae at the studied concentrations. Moreover, compound 13 and 15 (used as a sodium salt and 
trifluoroacetic acid salt, respectively), were also water soluble and also did not produce any 
toxicity at the studied concentrations. On the other hand, all the water insoluble di-tert-butyl 
phenolic compounds (10 - 12, 14, and 16) and benzopyran 17 showed more that 46% mortality 
of larvae at 1000 µg/mL concentration. Interestingly, 2,4-di-tert-butyl-6-(3-methylbut-2-en-1-
yl)phenol 16 was found to have similar toxicity towards the larvae as compared to MON-0585 at 
both studied concentrations. Compound 14 and benzopyran 17 also produced significant toxicity 
to the mosquito larvae with mortality of 93% and 91% at the concentration of 1000 µg/mL. In a 
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similar study by Spafford et al., it was found that methoprene, an insect growth regulator and 
commonly used insecticides caused about 60% mortality at 100 μg/L in 3 days bioassay against 
the third-instar larvae of Culex molestus.
30
 Therefore, compound 16 appears to have higher 
toxicity than methoprene towards mosquito larvae. In comparison to the water soluble di-tert-
butyl phenolic compounds (sodium salt of 13 and trifluoroacetic acid salt of amine 15), 
dihydroquinone, and compound 4; water insoluble di-tert-butyl phenolic compounds including 
10 – 12, 14, 16, and benzopyran 17 were found to be toxic to the larvae. This suggests that the 
water insoluble compounds, but not the water soluble compounds, may be absorbed through the 
body of the larvae resulting in its death.  
The larvae treated with di-tert-butyl phenolic compounds died over the course of 3 days 
indicating a target different from the neurological system, a common target in case of most 
insecticides. The treated larvae died before pupation.  
To better understand the effect of compound 16 on the larvae, the microscopic sections of 
the larvae killed by compound 16 were compared with that of untreated larvae as shown Figure 
7. The larvae treated with compound 16 had thin cuticle and appeared to start molting; however, 
failed to remove the old cuticle. Moreover, the larvae treated with compound 16 showed very 
little synthesis of new pupal cuticle as compared to the untreated larvae. This phenomenon was 
observed in all the three parts of the insect studied that is head, thorax, and abdomen. This 
indicated that the compound 16, other toxic di-tert-butyl phenolic derivative and compound 17 
might attack the target related to the insect cuticle formation. However, the target and 
mechanism of action of these water insoluble di-tert-butyl phenolic compounds and benzopyran 
17 needs to be investigated. 
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Head of treated larva (100X)
Head of control larva- 100X
Head of treated larva (400X)
Head of control larva-400X 
Old cuticle
Old cuticle
New cuticle
 
Figure 7: Microscopic slides of larvae of Anopheles gambiae both treated and untreated with 
compound 16.
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 Figure reprinted from Prasain et al. Bioorganic & Medicinal Chemistry. 2012, 
20, 1679-1689 with permission from Elsevier (copyright © 2012).  
  
 1.5 Conclusions 
Since laccase are known to oxidize phenolic compounds during cuticle sclerotization or 
tanning, various phenolic compounds containing halide, hydroxyl, aldehyde, methoxy, amino, 
and di-tert-butyl functions were synthesized and their redox potential, laccase oxidation, and 
mosquito anti-larval activities were examined. Synthesized phenolic compounds 1 - 8 were 
found to be laccase substrates but not the inhibitors of laccase. An inverse correlation between 
the oxidation potentials and the laccase oxidation activities of these compounds including some 
known laccase substrates such as dihydroquinone, catechol, 2-aminophenol, 1-2-
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phenylenediamine, and ABTS was established indicating that the compounds with lower 
oxidation potential had higher laccase activities.  
   Mosquito anti-larval activity studies showed that water insoluble di-tert-butyl substitited 
compound 14, 16, and 17 were found to have potent anti-larval activity. Moreover, compound 16 
had similar anti-larval activity as compared to that of MON-0585. The mode of action of 
compound 16 and its target in the disruption of the cuticle formation in mosquito larvae needs 
further investigation.  
 
1.6 Experimental Section 
General Methods 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Unity plus 400 
MHz or 200 MHz spectrometer for 
1
H and 
13
C in deuteriochloroform (CDCl3), unless otherwise 
indicated. Tetramethylsilane was used as the internal reference and the data reported in ppm. 
Infrared (IR) spectra were recorded on a Nicolet 380 FT-IR and are reported in wavenumbers 
(cm
-1
).  High-resolution Mass spectra were recorded on LCT Premier (Waters corp., Milford 
MA), a time of flight mass analyzer with an electrospray ion source.  Column chromatography 
was carried out on silica gel (200 – 400 mesh) from Natland International Corporation. 
Tetrahydrofuran (THF) and diethyl ether were dried and distilled over sodium and 
benzophenone, methylene chloride was dried and distilled over calcium hydride (CaH), and 
toluene was dried and distilled over LiAlH4.  The purity of compounds, 1 - 17 and MON 0585 
were found to be ~ 98% as indicated by HPLC analysis carried on Varian Prostar 210 with a UV-
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Vis detector and a reverse phase column from Phonomenex (250 x 21.20 mm, 10 micron, S. No: 
552581-1).  
 
Experimental section for synthesis 
4-(tert-Butyldimethylsilyloxy)-3-chloro-5-methoxybenzaldehyde (22) 
 
  To a solution of 400 mg (2.15 mmol) of 3-chloro-4-hydroxy-5-methoxybenzaldehyde 
(1)
42
 in 5 mL of dichloromethane at 0
o
C under argon, were added 0.6 mL (4.3 mmol) of 
triethylamine, 40 mg (0.33 mmol) of 4-dimethylaminopyridine (DMAP), and 648 mg (4.3 mmol) 
of tert-butyldimethylsilyl chloride and the solution was stirred at 25
o
C for 12 hours. The reaction 
was diluted with 100 mL of diethyl ether and washed with 20 mL of saturated aqueous NH4Cl 
solution, 20 mL of water, and 20 mL of brine. The organic layer was dried over anhydrous 
MgSO4, solvent evaporated, and the crude was column chromatographed on silica gel using a 
mixture of hexane and diethyl ether (4:1) as eluent to give 550 mg of 4-(tert-
butyldimethylsilyloxy)-3-chloro-5-methoxybenzaldehyde (22) in 85% yield. 
1H NMR δ 9.76 (s, 
1 H), 7.45 (d, J = 2.0 Hz, 1 H), 7.27 (d, J = 2.0 Hz, 1 H), 3.85 (s, 3 H), 1.01 (s, 9 H), 0.21 (s, 6 
H); 
13C NMR δ 190.0, 151.9, 147.7, 130.0, 126.6, 126.3, 108.4, 55.6, 25.8 (3 C), 19.0, -3.8 (2 C); 
HRMS calcd for C14H22ClO3Si (M+H
+
) 301.1021, found 301.1028. 
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4-(tert-Butyldimethylsilyloxy)-3-chloro-5-methoxyphenyl formate (23) & 4-(tert-
butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (24)  
 
 
  To a solution of 600 mg (2 mmol) of 4-(tert-butyldimethylsilyloxy)-3-chloro-5-
methoxybenzaldehyde (22) in 5 mL of dichloromethane at 0
o
C under argon, was added 750 mg  
(3 mmol) of m-chloroperbenzoic acid (70% pure) and heated to reflux for 8 hours. The reaction 
was cooled to room temperature and 5 mL of aqueous sodium thiosulfate and 200 mL of diethyl 
ether were added to it. The solution was washed with 20 mL of saturated aqueous NaHCO3, 20 
mL of water, and 20 mL of brine. The organic layer was dried over anhydrous MgSO4, solvent 
evaporated, and the crude was column chromatographed on silica gel using a mixture of hexane 
and diethyl ether (5:1) as eluent to give 400 mg of 4-(tert-butyldimethylsilyloxy)-3-chloro-5-
methoxyphenyl formate (23) and 150 mg of 4-(tert-butyldimethylsilyloxy)-3-chloro-5-
methoxyphenol (24) in 63% and 27% yield, respectively. Formate 23:  
1H NMR δ 8.26 (s, 1H, 
OCHO), 6.78 (d, J = 2.9 Hz, 1 H), 6.58 (d, J = 2.9 Hz, 1 H), 3.80 (s, 3 H), 1.03 (s, 9 H), 0.20 (s, 
6 H); 
13C NMR δ 159.3, 151.8, 143.2, 140.4, 125.9, 114.4, 104.1, 55.7, 26.0, 19.0, -3.9; HRMS 
calcd for C14H22ClO4Si (M+H
+
) 317.0976, found 317.0968.  Phenol 24: 
 1H NMR δ 6.43 (d, J = 
2.9 Hz, 1 H), 6.32 (d, J = 2.9 Hz, 1 H), 3.78 (s, 3 H), 1.02 (s, 9 H), 0.17 (s, 6 H); 
13C NMR δ 
152.2, 149.8, 135.8, 125.7, 108.2, 99.2, 55.5, 26.1 (3 C), 19.0, -4.0 (2 C); HRMS calcd for 
C13H22ClO3Si (M+H
+
) 289.1027, found 289.1000. 
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Conversion of formate 23 to phenol 24  
To a solution of 45 mg (0.142 mmol) of 4-(tert-butyldimethylsilyloxy)-3-chloro-5-
methoxyphenyl formate (23) in 2 mL of methanol, was added 98 mg (0.71 mmol) of K2CO3 and 
stirred at 25
o
C for 4 hours. The reaction was diluted with 100 mL of diethyl ether and washed 
with 10 mL of aqueous NH4Cl, 10 mL of water, and 10 mL of brine. The organic layer was  
dried over anhydrous MgSO4, solvent evaporated, and the crude was column chromatographed 
on silica gel using a mixture of hexane and diethyl ether (2:1) as eluent to give 37 mg of phenol 
24 in 90% yield, which 
1
H NMR spectrum is identical to that described above.  
 
2-Bromo-4-(tert-butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (25) & 2-bromo-3-
chloro-5-methoxy-1,4-benzoquinone (19) 
 
 
To a solution of 84 mg (0.29 mmol) of 4-(tert-butyldimethylsilyloxy)-3-chloro-5-
methoxyphenol (24) in 2 mL of DMF under argon, was added 57 mg (0.32 mmol) of NBS and 
was stirred at 25
o
C for 12 h.  The reaction solution was diluted with 100 mL of diethyl ether and 
washed with 10 mL of water followed by 10 mL of brine. The organic layer was dried over 
anhydrous MgSO4, solvent evaporated, and the crude was column chromatographed on silica gel 
using a gradient mixture of hexane and diethyl ether as eluent to give 27 mg of 2-bromo-4-(tert-
butyldimethylsilyloxy)-3-chloro-5-methoxyphenol (25) and 35 mg of 2-bromo-3-chloro-5-
methoxy-1,4-benzoquinone (19) in 31% and 48% yield, respectively.  Bromophenol 25:  
1
H 
NMR δ 6.56 (s, 1 H), 5.33 (s, 1 H, OH), 3.78 (s, 3 H), 1.03 (s, 9 H), 0.18 (s, 6 H); 13CNMR δ 
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151.5, 147.4, 136.8, 125.8, 101.5, 98.4, 55.6, 26.1, 19.0, -3.9; HRMS calcd for C13H19BrClO3Si 
(M-H) 364.9975, found 365.0076; C13H20BrClO3SiNa (M+Na
+
) 388.9951, found 388.9934.  p-
Benzoquinone 16 (light yellow solid): Mp. 167 – 170oC; IR (neat) υ 2953, 2913, 2839, 1683, 
1638, 1613, 1556, 1454, 1229, 1168 cm
-1
; 
1H NMR δ 6.16 (s, 1 H), 3.89 (s, 3 H); 13C NMR δ 
177.5, 172.4, 158.9, 137.4, 107.9, 107.2, 57.3; HRMS calcd for C7H5BrClO3 (M+1
+
) 250.9105, 
found 251.0593. 
Conversion of silyl ether 25 to p-benzoquinone 19 
To a solution of 25 mg (0.068 mmol) of silyl ether 25 in 2 mL of THF was added 68 µL 
(0.068 mmol) of n-Bu4NF (1 M in THF) and stirred under argon from 0
o
C for 30 minutes. The 
reaction was diluted with 50 mL of diethyl ether and washed with 10 mL of aqueous NH4Cl, 10 
mL of water, and 10 mL of brine. The organic layer was dried over anhydrous MgSO4, solvent 
evaporated, and the crude was column chromatographed on silica gel using a mixture of hexane 
and diethyl ether (1:1) as eluent to give 14 mg of p-benzoquinone 19 in 81% yield, which 
1
H 
NMR spectrum is identical to that described above.   
 
2-Bromo-3-chloro-5-methoxy-1,4-dihydroxybenzene (2) 
 
  A mixture of 10 mg (0.040 mmol) of 2-bromo-3-chloro-5-methoxy-1,4-benzoquinone 
(19) and 2 mg of 10% palladium over carbon in 1 mL of ethanol under 1 atm. of hydrogen (a 
balloon filled with hydrogen connected to the round bottom flask) was stirred at 25
o
C for 15 
minutes, filtered through Celite, and rinsed with 10 mL of ethanol.  The filtrate was concentrated 
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to give 10 mg of 2-bromo-3-chloro-5-methoxy-1,4-dihydroxybenzene (2) in quantitative yield: 
IR (neat) υ 3303, (s), 2935, 2851, 1601, 1497, 1441, 1210, 1071, 1046, 994, 864, 842, 825 cm-1; 
1H NMR δ 6.60 (s, 1 H), 5.50 (bs, 1 H, OH), 5.30 (bs, 1 H, OH), 3.89 (s, 3 H, OMe); 13C NMR δ 
148.2, 147.7, 136.7, 121.1, 100.2, 99.4, 56.0; HRMS calcd for C7H6BrClO3 (M
+
) 251.9189, 
found 252.0427. 
 
3-Chloro-4,5-dihydroxybenzaldehyde (3)
42
 
 
To a solution of 10.14 g (5.43 mmol) of 3-chloro-4-hydroxy-5-methoxybenzaldehyde 
(1)
42
 in 40 mL of dry CH2Cl2 at 0
o
C, was added 564 µL (6 mmol) of boron tribromide (BBr3)  
drop wise and the mixture was stirred under argon at 0
o
C for 30 minutes and then at 25
o
C for 12 
hours. The reaction was quenched with the slow addition of 50 mL of methanol followed by the 
solvent evaporation under rotavap. The addition and evaporation of methanol were repeated 3 
times (50 mL each time) to remove excess BBr3. The crude was then treated with 30 mL of 1:1 
hexane and diethyl ether solution,  filtered and washed with small amount of 1:1 hexane and 
diethyl ether solution to get 8.8 g (93.9%) of 3-chloro-4,5-dihydroxybenzaldehyde (3)
42
 as pure 
green solid. 
1
H NMR (Acetone-d6) δ  9.78 (s, 1H), 7.47 (d, J = 2.0 Hz), 7.34 (d, J = 2.0 Hz); 13C 
NMR (Acetone-d6) δ 190.6, 148.8, 147.4, 130.8, 125.2, 121.5, 113.8. 
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3,4-Bis(tert-butyldimethylsilyoxy)-5-chlorobenzaldehyde (26)
42
 
 
To a solution of 800 mg (4.64 mmol) of 3-chloro-4,5-dihydroxybenzaldehyde (3)
42
 and 
170 mg (1.39 mmol) of 4-dimethylaminopyridine (DMAP) in 10 mL of dry CH2Cl2 at 0
o
C under 
argon, were added 2.6 mL (18.56 mmol) of triethyl amine and 2.8 g (18.56 mmol) of tert-
butyldimethylsilyl chloride and stirred at 0
o
C for 1 hour and then at 25
o
C for 3 hours. The 
reaction was diluted with 100 mL of diethyl ether, washed with 20 mL of NH4Cl (aq.) followed 
by 20 mL of brine, dried over anhydrous MgSO4, and the solvent evaporated. The crude was 
column chromatographed on silica gel using a 10:1 mixture of hexane and diethyl ether as eluent 
to give 1.46 g of desired 3,4-bis(tert-butyldimethylsilyoxy)-5-chlorobenzaldehyde (26)
42
 in 79% 
yield.
 1H NMR δ 9.78 (s, 1 H), 7.50 (d, J = 2 Hz, 1 H), 7.29 (d, J = 2 Hz, 1 H), 1.05 (s, 9 H), 0.99 
(s, 9 H), 0.27 (s, 6 H), 0.24 (s, 6 H); 
13C NMR δ 190.1, 149.9, 149.4, 130.3, 128.0, 126.0, 119.0, 
26.3 (3 C), 26.2 (3 C), 19.0, -3.2, -3.4; HRMS calcd for C19H34ClO3Si2 (M+H
+
) 401.1735, found 
401.1747. 
 
3,4-Bis(tert-butyldimethylsilyloxy)-5-chlorophenyl formate (27)
42
 
 
To a solution of 1.014 g (5.43 mmol) of the 3,4-bis(tert-butyldimethylsilyoxy)-5-
chlorobenzaldehyde (26) in 20 mL of dry CH2Cl2 was added 1.6 g (6.45 mmol) of m-
chloroperoxybenzoic acid (70% pure) and refluxed at 50
o
C for 10 hours. The reaction was 
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diluted with 500 mL of diethyl ether, washed with 100 mL of NaHCO3 (aq.), 100 mL of water 
and 100 mL of brine. The organic layer was dried over anhydrous MgSO4, solvent evaporated, 
and the crude was column chromatographed on silica gel using a mixture of diethyl ether and 
hexane (10:1) as eluent to give 1.42 g  of 3,4-bis(tert-butyldimethylsilyloxy)-5-chlorophenyl 
formate (27)
42
 in 79% yield . 
1
H NMR δ 8.22 (s, 1 H, OCHO), 6.79 (d, J = 3.2 Hz, 1 H), 6.58 (d, 
J = 3.2 Hz, 1 H), 1.03 (s, 9 H, t-Bu), 0.96 (s, 9 H, t-Bu), 0.22 (s, 6 H, Me), 0.19 (s, 6 H, Me); 
13
C 
NMR δ 159.0 (CHO), 148.8, 143.0, 142.4, 127.1, 115.5, 113.1, 26.2 (6 C, t-Bu), 18.8 (2 C, t-Bu), 
-3.3 (2 C, Me), -3.6 (2 C, Me). 
 
3,4-Bis(tert-butyldimethylsilyloxy)-5-chlorophenol (28)
42
 
 
To a solution of 1.24 g (3 mmol) of 3,4-bis(tert-butyldimethylsilyloxy)-5-chlorophenyl 
formate (27) in 30 mL of methanol, was added 2.21 g (15 mmol) of K2CO3 and stirred at room 
temperature for overnight. The reaction was diluted with 70 mL ethyl acetate and washed with 
20 mL of NH4Cl (aq.) followed by 20 mL of brine. The organic layer was dried over anhydrous 
MgSO4 and solvent evaporated to give 0.6 g of 3,4-bis(tert-butyldimethylsilyloxy)-5-
chlorophenol (28)
42
 which was used in the next step without further purification. 
1
H NMR δ 6.47 
(d, J = 2.9 Hz, 1 H), 6.30 (d, J = 2.9 Hz, 1 H), 1.02 (s, 9 H, t-Bu), 0.97 (s, 9 H, t-Bu), 0.22 (s, 6 
H, Me), 0.17 (s, 6 H, Me); 
13
C NMR δ 149.7, 148.9, 137.7, 126.9, 109.8, 107.8, 26.3 (3 C), 26.2 
(3 C), -3.6 (2C, Me), -3.4 (2 C, Me). 
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2-Bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-chlorophenol (29)
42
 
 
To a solution of 420 mg (1.08 mmol) of 3,4-bis(tert-butyldimethylsilyloxy)-5-
chlorophenol (28) in 8 mL of dry DMF under argon at 25
o
C, was added 191.2 mg (1.08 mmol) 
of N-bromosuccinimide and stirred for 22 hours. The reaction was diluted with 50 mL of ethyl 
acetate and washed twice with 15 mL of water followed by 15 mL of brine. The organic layer 
was dried over anhydrous MgSO4, solvent evaporated, and the crude was column 
chromatographed using a gradient mixture of hexane and diethyl ether as eluent to give 182 mg 
of 2-bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-chlorophenol (29)
42
 in 63% yield; based on the 
recovery of 178 mg of starting material 28. 
1H NMR δ 6.65 (s, Ar, 1 H), 5.27 (s, OH), 1.03 (s, t-
Bu,  9 H), 0.97 (s, t-Bu,  9 H), 0.23 (s, CH3, 6 H), 0.17 (s, CH3, 6 H); 
13C NMR δ 148.3, 147.4, 
138.8, 127.0, 106.9, 102.9, 26.2 (t-Bu), 18.8, -3.3 (Me), -3.5 (Me). 
 
2-Bromo-4,5-bis-(tert-butyldimethylsilyloxy)-3-chloro-1-methoxybenzene (30) 
 
   To a solution of 100 mg (0.21 mmol) of 2-bromo-4,5-bis(tert-butyldimethylsilyloxy)-3-
chlorophenol (29)
 
in 2 mL of dichloromethane at 0
o
C and  under argon, were added 55 mg (0.26 
mmol) of proton sponge and 38 mg (0.26 mmol) of trimethyloxonium tetrafluoroborate, and the 
mixture was stirred at 0
o
C for 8 h.  The reaction was diluted with 15 mL of water and extracted 
twice with 50 mL of diethyl ether. The organic layer was washed with 10 mL of water followed 
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by 10 mL of brine, dried over anhydrous MgSO4, solvent evaporated, and the crude was column 
chromatographed on silica gel using a mixture of hexane and diethyl ether (10:1) as eluent to 
give 67 mg of 2-bromo-4,5-bis-(tert-butyldimethylsilyloxy)-3-chloro-1-methoxybenzene (30) in 
95% yield; based on the recovery of 31 mg of compound 29.  
1H NMR δ 6.43 (s, 1 H), 3.80 (s, 3 
H), 1.03 (s, 9 H), 0.98 (s, 9 H), 0.23 (s, 6 H), 0.17 (s, 6 H); 
13C NMR δ 151.0, 147.5, 138.9, 
128.9, 104.7, 104.5, 56.9, 26.3 (6 C), 18.9, 18.8, -3.3 (2 C), -3.5 (2 C); HRMS calcd for 
C19H35BrClO3Si2 (M+H
+
) 481.0996, found 481.0951. 
 
4-Bromo-3-chloro-5-methoxybenzene-1,2-diol (4) 
 
  To a solution of 51 mg (0.10 mmol) of 2-bromo-4,5-bis-(tert-butyldimethylsilyloxy)-3-
chloro-1-methoxybenzene (30) in 2 mL of THF at 0
o
C under argon, was added 0.20 mL (0.20 
mmol) of n-Bu4NF, and the solution was stirred for 30 min.  The reaction was diluted with 100 
mL of diethyl ether, washed with 10 mL of water followed by 10 mL of brine, dried over 
anhydrous MgSO4, solvent evaporated, and the crude column chromatographed on silica gel 
using a gradient mixture of dichloromethane and methanol as eluent to give 19 mg of 4-bromo-3-
chloro-5-methoxybenzene-1,2-diol (4) in 71% yield.  IR (neat) υ 3436, 3219 (broad & s), 2917, 
2851, 1580, 1462, 1417, 1315, 1188, 1070, 984, 820 cm
-1
; 
1
H NMR δ 6.59 (s, 1 H), 5.60 (bs, 1 
H, OH), 5.24 (bs, 1 H, OH), 3.83 (s, 3 H); 
13
C NMR δ 151.4, 144.4, 134.2, 121.8, 101.7, 99.7, 
57.1; HRMS calcd. for C7H7BrClO3 C7H7BrClO3 (M+H
+
) 252.9267, found 252.9254.  
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3-(tert-Butyldimethylsilyloxy)-5-chloro-4-hydroxybenzaldehyde (31) 
 
   To a solution of 3.2 g (19 mmol) of 3-chloro-4,5-dihydroxybenzaldehyde (3) in 60 mL of 
CH2Cl2 at 0
o
C under argon, were added 2.9 mL (22 mmol) of triethylamine, 0.45 g (3.7 mmol) of 
4-dimethylaminopyridine, and 3.4 g (22 mmol) of tert-butyldimethylsilyl chloride and the 
solution was stirred at 25
o
C for 8 h.  The reaction was diluted with 500 mL of diethyl ether and 
washed with 50 mL water and 50 mL of brine. The organic layer was dried over anhydrous 
MgSO4, solvent evaporated, and the crude was column chromatographed on silica gel using 
hexane and dichloromethane (1:1) as eluent to give 3.7 g of 3-(tert-butyldimethylsilyloxy)-5-
chloro-4-hydroxybenzaldehyde (31) and 0.84 g of 5-chloro-3,4-bis-(tert-butyldimethylsilyloxy) 
benzaldehyde (26) in 70% and 11% yield, respectively.  Compound 31 was crystallized from 
diethyl ether to provide single crystals and its structure was unequivocally identified by a single-
crystal X-ray analysis (Figure 5). Compound 31: 
1H NMR δ 9.76 (s, 1H, CHO), 7.51 (d, J = 2.8 
Hz, 1 H), 7.27 (d, J = 2.8 Hz, 1 H), 6.24 (s, 1 H, OH), 1.03 (s, 9 H), 0.32 (s, 6 H); 
13C NMR δ 
189.9, 149.9, 144.2, 129.4, 126.8, 120.7, 115.9, 25.8, 18.4, -4.2; HRMS calcd for C13H20ClO3Si  
(M+H
+
) 287.0870, found 287.0858. Compound 26: 
1H NMR δ 9.78 (s, 1 H), 7.50 (d, J = 2 Hz, 
1 H), 7.29 (d, J = 2 Hz, 1 H), 1.05 (s, 9 H), 0.99 (s, 9 H), 0.27 (s, 6 H), 0.24 (s, 6 H); 
13C NMR δ 
190.1, 149.9, 149.4, 130.3, 128.0, 126.0, 119.0, 26.3 (3 C), 26.2 (3 C), 19.0, -3.2, -3.4; HRMS 
calcd for C19H34ClO3Si2 (M+H
+
) 401.1735, found 401.1747. 
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3-(tert-Butyldimethylsilyloxy)-5-chloro-4-methoxybenzaldehyde (32) 
 
To a solution of 450 mg (1.57 mmol) of 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
hydroxybenzaldehyde (31) in 10 mL of dichloromethane at 0
o
C under argon, were added 673 mg 
(3.14 mmol) of proton sponge and 465 mg (3.14 mmol) of trimethyloxonium tetrafluoroborate, 
and stirred at 0
o
C for 12 hours.  The reaction mixture was diluted with 200 mL of diethyl ether 
and washed with 30 mL of aqueous NH4Cl solution, 30 mL of water, and 30 mL of brine. The 
organic layer was dried over anhydrous MgSO4, solvent evaporated, and the crude was column 
chromatographed on silica gel using a mixture of hexane and diethyl ether (10:1) as eluent to 
give 200 mg of  3-(tert-butyldimethylsilyloxy)-5-chloro-4-methoxybenzaldehyde (32) in 78% 
yield; based on the recovery of 206 mg of 31 : 
1H NMR δ 9.83 (s, 1H, CHO), 7.54 (d, J = 1.8 Hz, 
1 H), 7.28 (d, J = 1.8 Hz, 1 H), 3.91 (s, 3 H), 1.03 (s, 9 H), 0.23 (s, 6 H); 
13C NMR δ 190.1, 
153.4, 150.9, 132.8, 129.8, 125.5, 119.9, 60.7, 25.8, 18.4, -4.4; HRMS calcd for C14H22ClO3Si 
(M+H
+
) 301.1027, found 301.1421; negative ion detection mode: C14H20ClO3Si (M-H) 
299.0870, found 298.9978. 
 
3-(tert-Butyldimethylsilyloxy)-5-chloro-4-methoxyphenyl formate (33) & 3-(tert-
butyldimethylsilyloxy)-5-chloro-4-methoxyphenol (34) 
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To a solution of 130 mg (0.432 mmol) of 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
methoxybenzaldehyde (32) in 2 mL of dichloromethane at 0
o
C and under argon, was added 160 
mg (70% pure; 0.648 mmol) of  m-chloroperbenzoic acid, and the solution was refluxed for 12 
hours.  The reaction solution was diluted with 5 mL of aqueous sodium thiosulfate and 200 mL 
of diethyl ether. The solution was washed with 20 mL water followed by 20 mL of brine. The 
organic layer was dried over anhydrous MgSO4, solvent evaporated, and the crude was column 
chromatographed on silica gel using a mixture of hexane and diethyl ether (10:1) as eluent to 
give 58 mg of 3-(tert-butyldimethylsilyloxy)-5-chloro-4-methoxyphenyl formate (33) and 55 mg 
of hydrolyzed product, 3-(tert-butyldimethylsilyloxy)-5-chloro-4-methoxyphenol (34) in 42% 
and 44% yield, respectively. Compound 33:
1H NMR δ 8.23 (s, 1 H, OCHO), 6.83 (d, J = 2.6 
Hz, 1 H), 6.59 (d, J = 2.6 Hz, 1 H), 3.81 (s, 3 H), 1.01 (s, 9 H), 0.21 (s, 6 H); 
13C NMR δ 158.9, 
150.7, 146.6, 145.4, 129.1, 115.8, 113.6, 60.7, 25.8 (3 C), 18.4, -4.5; HRMS calcd for 
C14H22ClO4Si (M+H
+
) 317.0976, found 317.1355. Compound 34:
 1H NMR δ 6.48 (d, J = 2.6 
Hz, 1 H), 6.29 (d, J = 2.6 Hz, 1 H), 3.75 (s, 3 H), 1.01 (s, 9 H), 0.20 (s, 6 H); 
13C NMR δ 152.0, 
150.7, 142.6, 128.1, 110.8, 108.6, 60.7, 25.8 (3 C), 18.4, -4.5; HRMS calcd for C13H22ClO3Si 
(M+H
+
) 289.1027, found 289.1041. 
Conversion of formate 33 to phenol 34 
A solution of 55 mg (0.182 mmol) of compound 33 and 126 mg (0.914 mmol) of K2CO3 
in 1 mL of methanol was stirred at 25
o
C for 12 h. The reaction was diluted with 10 mL of water 
and 30 mL of ethyl acetate and the solution washed with 5 mL of aqueous NH4Cl solution, 5 mL 
of water, and 5 mL of brine. The organic layer was dried over anhydrous MgSO4, solvent 
evaporated, and the crude was column chromatographed on silica gel using a mixture of hexane 
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and diethyl ether (10: 1) as eluent to give 50 mg of compound 34 in quantitative yield, which 
1
H 
NMR spectrum is identical to that described above. 
 
2-Bromo-5-(tert-butyldimethylsilyloxy)-3-chloro-4-methoxyphenol (35) 
 
   To a solution of 75 mg (0.26 mmol) of 3-(tert-butyldimethylsilyloxy)-5-chloro-4-
methoxyphenol (34) in 2 mL of dimethylformamide (DMF) under argon, was added 51 mg (0.28 
mmol) of N-bromosuccinimide and the solution was stirred at 25
o
C for 12 h.  The reaction was 
diluted with 100 mL of diethyl ether, washed with 10 mL of water followed by 10 mL of brine, 
and the organic layer was dried over anhydrous MgSO4. The solvent was evaporated and the 
crude was column chromatographed on silica gel using a mixture of hexane and diethyl ether 
(10:1) as eluent to give 64 mg of 2-bromo-5-(tert-butyldimethylsilyloxy)-3-chloro-4-
methoxyphenol (35) in 67% yield:  Mp. 44 – 45oC; 1H NMR δ 6.55 (s, 1 H), 5.42 (s, 1 H, OH), 
3.77 (s, 3 H), 1.01 (s, 9 H), 0.20 (s, 6 H); 
13C NMR δ 150.2, 149.6, 143.1, 124.2, 107.2, 103.0, 
60.8, 25.8 (3 C), 18.5, -4.5; HRMS calcd for C13H21BrClO3Si (M+H
+
) 367.0132, found 
367.0142. 
 
4-Bromo-5-chloro-6-methoxybenzene-1,3-diol (5) 
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  To a solution of 40 mg (0.108 mmol) of 2-bromo-5-(tert-butyldimethylsilyloxy)-3-
chloro-4-methoxyphenol (35) in 2 mL of dry THF under argon at 0
o
C, was added 120 µL (0.12 
mmol) of n-Bu4NF (1 M solution in THF) and the solution was stirred at 0
o
C for 30 min.  The 
reaction was diluted with 70 mL of diethyl ether, washed with 10 mL of water followed by 10 
mL of brine, and the organic layer was dried over anhydrous MgSO4. The solvent was 
evaporated and the crude was column chromatographed on silica gel using a mixture of ethyl 
acetate and hexane (2:1) as eluent to give 15 mg of 4-bromo-5-chloro-6-methoxybenzene-1,3-
diol (5) in 60% yield.  IR (neat) υ 3321 (bs), 3260, 2917, 1589, 1421, 1241, 984, 800; 1H NMR δ 
6.65 (s, 1 H), 3.87 (s, 3 H); 
13C NMR δ 150.5, 150.0, 138.7, 127.5, 101.8, 101.7, 61.5; HRMS 
calcd for C7H7BrClO3 (M+H
+
) 252.9267, found 252.9279. 
 
2-Bromo-3-chloro-4,5-dibenzyloxyphenol (37) 
 
   To a solution of 100 mg (0.188 mmol) of (4,5-bis(benzyloxy)-2-bromo-3-
chlorophenoxy)(tert-butyl)dimethylsilane (36)
42
 in 3 mL of tetrahydrofuran (THF) at 0
o
C, was 
added 210 µL of n-Bu4NF (1 M in THF) and stirred under argon at 0
o
C for 30 minutes.  The 
solution was diluted with 100 mL of diethyl ether, washed with 10 mL of water followed by 10 
mL of brine, and the organic layer was dried over anhydrous MgSO4. The dry organic layer was 
concentrated and the crude was column chromatographed on silica gel using a mixture of hexane 
and diethyl ether (10:1) as eluent to give 56 mg of 2-bromo-3-chloro-4,5-dibenzyloxyphenol (37) 
as white solids in 74% yield. Mp.= 108 – 110oC; 1H NMR δ  7.40 - 7.20 (m, 10 H), 6.66 (s, 1 H), 
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5.07 (s, 2 H), 4.96 (s, 2 H);  
13C NMR δ 153.1, 149.9, 139.8, 137.0, 136.1, 129.2, 128.8, 128.5, 
128.44, 128.40, 127.6, 102, 100.6, 75.4, 71.3; HRMS calcd for C20H17BrClO3 (M+H
+
) 419.0044, 
found 419.0051. 
 
5-Bromo-6-chlorobenzene-1,2,4-triol (6) 
 
To a solution of 25 mg (0.06 mmol) of 2-bromo-3-chloro-4,5-dibenzyloxyphenol (37) in 
1 mL of ethanol, was added 2.5 mg of 10% palladium/carbon and was stirred under 1 atmosphere 
of hydrogen (a balloon filled with hydrogen was connected to the round bottom flask) at 25
o
C for 
3 h. The reaction mixture was filtered through Celite and concentrated to dryness to give 13 mg 
of 5-bromo-6-chlorobenzene-1,2,4-triol (6) in 93% yield. The triol 6 was stored in a dry box 
under nitrogen atmosphere:  Mp. >350
o
C; IR (neat) υ 3382 (bs, OH stretch), 2932, 2843, 1614, 
1437, 1285, 1170, 1070 cm
-1
; UV (in methanol)  209.6 (εmax = 30300), 291.8 (1250; likely 
derived from a partial oxidation of the polyphenol functions), 332.5 (4640), 397.1 (1785) nm;  
1
H NMR (CD3OD) δ 6.66 (s, 1 H, Ar), 5.58 (bs, 1 H, OH), 5.27 (bs, 1 H, OH), 5.21 (bs, 1 H, 
OH); 
13
C NMR (CD3OD) δ 149.4, 147.6, 137.4, 123.1, 103.2, 100.6; HRMS calcd for 
C6H5BrClO3 (M+H
+
) 238.9105, found 238.9111.  
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2-Amino-4-(hydroxymethyl)phenol (7)
35
 &  2-amino-4-methylphenol (8)
36
  
 
   To a solution of 300 mg (1.8 mmol) of 4-hydroxy-3-nitrobenzaldehyde (38)  in 30 mL of 
ethanol was added 150 mg of 10% palladium over carbon and shaken on a hydrogenator under 
30 psi atmosphere of hydrogen for 4 h.  The reaction was filtered through Celite, and the Celite 
was carefully rinsed with 30 mL ethyl acetate. The filtrate was concentrated and the crude was 
column chromatographed on silica gel using a mixture of dichloromethane and methanol (9:1) as 
eluent to give 104 mg of 2-amino-4-(hydroxymethyl)phenol (7)
35
 and 91 mg of 2-amino-4-
methylphenol (8)
36
, both in 41% yield. Compound 7: IR (neat) υ 3387 (sharp, m), 3313 (sharp, 
m), 3047 (broad), 2802, 1605, 1515, 1454, 1364, 1286, 1221, 1155, 1008, 816 cm
-1
;  
1
H NMR 
(D2O) δ 6.88 (d, J = 1.2 Hz, 1 H), 6.85 (d, J = 8 Hz, 1 H), 6.77 (dd, J = 8, 1.2 Hz, 1 H), 4.49 (s, 2 
H); 
13
C NMR (DMSO-d6) δ 144.9, 136.1, 133.4, 114.9, 113.8, 113.4, 63.3.Compound 8: IR 
(neat) υ 3370 (sharp, m), 3301 (sharp, m), 2921, 1601, 1519, 1458, 1388, 1286, 878, 800 cm-1; 
1H NMR δ 6.62 (d, J = 7.6 Hz, 1 H), 6.58 (d, J = 1.6 Hz, 1 H), 6.48 (dd, J = 7.6, 1.6 Hz, 1 H), 
2.21 (s, 3 H); 
13C NMR δ 141.9, 134.4, 131.2, 120.0, 118.1, 115.4, 20.9.   
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1-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (9)
46
 
 
 
To 1 g (7.5 mmol) of anhydrous AlCl3 under argon was added 1mL (9.5 mmol) of 
isobutyryl chloride (40) at -10
o
C followed by 1.2 g (5.8 mmol) of 2,6-di-tert-butylphenol (39). 
To the reaction mixture, 1 mL (9.5 mmol) of isobutyryl chloride was again added and shaken 
vigorously for 15 minutes till light pink paste was formed. The reaction was quenched with 50 
mL of ice cold water and extracted thrice with 50 mL of ethyl ether. The combined organic 
layers were washed with 20 mL brine, dried over anhydrous MgSO4 and solvent evaporated to 
give 1.4208 g of 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (9)
46
 in 90% 
yield. Thin layer chromatography (TLC) and NMR analysis indicated that the compound was 
pure and was used in the next step without further purification.
1H NMR δ 7.89 (S, Ar, 2 H), 5.71 
(s, OH, 1 H), 3.55 (m, 1 H), 1.48 (s, t-Bu, 18 H), 1.25 (d, J = 6.6 Hz, CH3, 6 H); 
13C NMR δ 
204.1, 158.4, 135.9, 127.9, 126.2, 34.91, 34.6, 30.3, 19.7. 
 
2-Bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (10)
47
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To a solution of 190 mg (0.69 mmol) of 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-
methylpropan-1-one (9) in a mixture of 0.5 mL of dry CH2Cl2 and 1 mL of dry ethyl acetate 
under argon, was added 375 mg (1.68 mmol) of cupric bromide and heated to reflux for 3 hours 
at 70
o
C. The reaction was filtered and solvent evaporated to give 234 mg of 2-bromo-1-(3,5-di-
tert-butyl-4-hydroxyphenyl)-2-methylpropan-1-one (10)
47
 as yellow colored solid in 96% yield. 
Thin layer chromatography (TLC) and NMR analysis indicated that the compound was pure and 
was used in the next step without further purification. 
1H NMR δ 8.17 (s, Ar, 2 H), 5.75 (s, OH, 1 
H), 2.06 (s, CH3, 6 H), 1.48 (s, t-Bu, 18 H); 
13C NMR δ 195.7 (C=O), 158.2, 135.6, 128.8, 125.6, 
60.6, 34.7, 32.4, 30.4. 
 
2,6-Di-tert-butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol (11)
47
 
 
To a solution of 230 mg (0.65 mmol) of 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)-
2-methylpropan-1-one (10) in 3 mL of dry ethyl ether at 0
o
C under argon, was added 55 mg 
(1.46 mmol) of LiAlH4 on vigorous stirring and refluxed at 55
o
C for 3 hours. The reaction was 
carefully quenched by the addition of 20 mL of water followed by the addition of 2 mL of 1M 
H2SO4. The reaction was then extracted with 100 mL of diethyl ether. The organic layer was 
washed with 20 mL of brine, dried over anhydrous MgSO4, and solvent evaporated to give 180 
mg of 2,6-di-tert-butyl-4-(1-hydroxy-2-methylpropan-2-yl)phenol (11)
47
 as white solid in 
quantitative yield. Thin layer chromatography (TLC) and NMR analysis indicated that the 
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compound was pure and was used in the next step without further purification.
1H NMR δ 7.19 (s, 
Ar, 2 H), 5.13 (s, Ar-OH, 1 H), 3.57 (d, J = 6.6 Hz, 2 H), 1.45 (s, t-Bu, 18 H), 1.33 (s, CH3, 6H); 
13
C NMR δ 152.2, 136.4, 135.6, 123.0, 73.6, 40.1, 34.8, 30.5, 25.7.  
 
2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal (12) 
 
 
To a solution of 170 mg (0.61 mmol) of 2,6-di-tert-butyl-4-(1-hydroxy-2-methylpropan-
2-yl)phenol (11) in 3 mL of dimethyl sulfoxide (DMSO), was added 0.21 g (0.73 mmol) of o-
iodoxybenzoic acid (IBX) and stirred under argon at 25
o
C for 12 h. The reaction was diluted 
with 200 mL of CH2Cl2, washed with 30 mL of water followed by 30 mL of brine, dried over 
anhydrous MgSO4, and the solvent evaporated to give 170 mg of 2-(3,5-di-tert-butyl-4-
hydroxyphenyl)-2-methylpropanal (12) in quantitative yield. Thin layer chromatography (TLC) 
and NMR analysis indicated that the compound was pure and was used in the next step without 
further purification.  IR (neat) υ 3603 (OH), 2952, 2900, 2700 (C-H aldehyde), 1714 (C=O 
aldehyde), 1435, 1360, 1230, 1141, 1120, 903, 826, 744;  
1H NMR δ 9.45 (s, 1 H, CHO), 7.06 (s, 
2 H, Ar), 5.22 (s, 1 H, OH), 1.44 (s, 24 H, Me); 
13C NMR δ 202.8 (C=O), 153.1, 136.2 (2 C), 
131.4, 123.6 (2 C), 50.4, 34.8, 30.4 (t-Bu), 22.7; MS negative mode: m/z 275.6 (M-1); positive 
mode: m/z 299.4 (M+Na
+
). 
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2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime (14) 
 
   To a solution of 40 mg (0.14 mmol) of 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-
methylpropanal (12) in 3 mL of acetonitrile and water (2:1), were added 25 mg (0.35 mmol) of 
NH2OH•HCl and 60 mg (0.43 mmol) of sodium acetate, and the solution was stirred at 25
o
C for 
1.5 h. The reaction was rotovaporated to remove acetonitrile, diluted with 20 mL of water, and 
extracted three times with diethyl ether (60 mL total). The combined extract was concentrated to 
give 41 mg of 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-methylpropanal oxime (14) in 97% yield. 
Thin layer chromatography (TLC) and NMR analysis indicated that the compound was pure. 
1
H 
NMR δ 7.49 (s, 1 H, CH=N), 7.12 (s, 2 H, Ar), 1.47 (s, 6 H, Me), 1.44 (s, 18 H, t-Bu); 13C NMR 
δ 158.7 (C=N), 152.5, 135.9, 135.7, 122.9 (2 C), 41.0, 34.7, 30.5 (6 C), 26.9; MS m/z 314 
(M+Na
+
). 
 
4-[(2-Benzylamino)-1,1-dimethylethyl]-2,6-di-tert-butylphenol (15) 
 
   To a solution of 50 mg (0.18 mmol) of 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-
methylpropanal (12) in 3 mL of toluene was added 19 µL (0.18 mmol) of benzylamine and 
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heated to reflux using a Diel’s Stark apparatus for 12 h. Toluene was evaporated under 
rotovapor, the crude was dissolved in 2 mL of methanol, and 18 mg (0.29 mmol) of NaCNBH3 
was added. The resulting solution was stirred for 2 h, diluted with 20 mL of water, and extracted 
twice with ethyl acetate (100 mL total).  The combined extract was washed with 10 mL of water 
and 10 mL of brine, dried over anhydrous MgSO4, and solvent evaporated to give 68 mg of 4-
((2-benzylamino)-1,1-dimethylethyl)-2,6-di-tert-butylphenol (15) in 98% yield. Thin layer 
chromatography (TLC) and NMR analysis indicated that the compound was pure. 
1H NMR δ 
7.35 – 7.18 (m, 5 H, Ph), 7.13 (s, 2 H, Ar), 5.08 (broad s, 1 H), 3.72 (s, 2 H, CH2N), 2.68 (s, 2 H, 
CH2N), 1.43 (s, 18 H, t-Bu), 1.33 (s, 6 H, Me); 
13C NMR δ 151.92, 140.4, 137.8, 135.4, 128.5, 
128.1, 127.0, 122.7, 61.5, 54.2, 38.6, 34.7, 30.6, 27.9; MS m/z 368.5 (M+1). 
 
 
2,4-Di-tert-butyl-6-(3-methyl-2-butenyl)phenol (16) and 6,8-di-tert-butyl-2,2-dimethyl-3,4-
dihydro-2H-chromene (17) 
 
  To a solution of 200 mg (1.44 mmol) of 2-methyl-3-buten-2-ol (42) in 3 mL of 
dichloromethane at -78
o
C under argon, were added 180 µL (1.44 mmol) of BF3•ether followed 
by 205 mg (0.96 mmol) of 2,4-di-tert-butylphenol (41).  The solution was warmed to 25
o
C and 
stirred for 1 h. The reaction was diluted with 200 mL of diethyl ether, washed with 20 mL of 
aqueous NaHCO3 followed by 20 mL of brine, the organic layer was dried over anhydrous 
Na2SO4, solvent evaporated, and the crude was column chromatographed on silica gel using 1% 
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diethyl ether in hexane as eluent to give 120 mg of 2,4-di-tert-butyl-6-(3-methyl-2-
butenyl)phenol (16)  and 26 mg of 6,8-di-tert-butyl-2,2-dimethyl-3,4-dihydro-2H-chromene (17) 
in 46% and 10% yield, respectively.  Compound 16:  
1H NMR δ 7.22 (d, J = 3 Hz, 1 H, Ar), 
6.99 (d, J = 3 Hz, 1 H, Ar), 5.34 (t,hept, J = 7, 1 Hz, 1 H, =CH), 3.37 (d, J = 7 Hz, 2 H, CH2), 
1.85 (s, 3 H, Me), 1.80 (s, 3 H, Me), 1.43 (s, 9 H, t-Bu), 1.31 (s, 9 H, t-Bu); 
13C NMR δ 151.5, 
142.3, 135.9, 135.7, 126.0, 125.0, 122.6, 122.3, 35.1, 34.4, 31.9 (3 C), 31.7, 30.0 (3C), 26.0, 
18.2; MS negative mode: m/z 273.8 (M-1). Compound 17:  
1H NMR δ 7.14 (d, J = 3 Hz, 1 H, 
Ar), 6.93 (d, J = 3 Hz, 1 H, Ar), 2.79 (t, J = 7 Hz, 2 H, CH2), 1.79 (t, J = 7 Hz, 2 H, CH2), 1.39 
(s, 9 H, t-Bu), 1.36 (s, 6 H, Me), 1.30 (s, 9 H, t-Bu); 
13C NMR δ 150.3, 141.0, 136.9, 124.2, 
121.8, 119.9, 73.9, 35.2, 34.3, 33.0, 31.9, 30.0, 27.3, 23.5; MS positive mode: m/z 275.2 (M+1). 
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Chapter 2. Inhibition of PKC phosphorylation by substituted 
quinolines (PQs)  
  
2.1 Introduction 
Protein kinases are enzymes that catalyze the transfer of a -phosphate group from 
adenosine triphosphate (ATP) to serine, threonine, or tyrosine residue of other proteins resulting 
in their phosphorylation and affecting their activities, cellular location, and protein-protein 
interaction.
1,2
 Protein kinase C (PKC) belongs to the family of serine/threonine protein kinases 
and was first reported by Yasutomi Nishizuka and his coworkers in several mammalian tissues in 
1977.
3,4
 Few years later, PKC was found to be activated by diacylglycerol (DAG) in cyclic 
adenosine monophosphate (cAMP) independent  but calcium and phospholipids dependent 
pathways and plays crucial role in signal transduction in several processes including cell 
proliferation, differentiation, migration, and apoptosis.
2,5,6
  
Activation of PKC by phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate 
(TPA), a well known tumor-promoting agent, has established the potential role of PKC in tumor 
promotion and progression and heightened PKC as potential target in anticancer therapy.
7
 
Phorbol esters are known to substitute diacylglycerol (DAG) with higher binding affinity 
towards PKC.
7
 Recognition of several isozymes of PKC with different mode of activation and 
tissue distribution has opened a door towards the development and use of isozymes-specific 
inhibitors targeting specific intracellular pathways and leading to the possible cure of cancer. 
Several broad spectrum and isozymes specific PKC inhibitors including staurosporine and its 
derivatives like 7-hydroxystaurosporine (UCN01) and N-benzoyl staurosporine (PKC412), 
tamoxifen, and ISIS3521 (an antisense phorothionate oligonucleotide) are known and found to 
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have anticancer properties but with low clinical efficiency that could be due to their poor 
specificity/selectivity towards PKC and its specific isozymes or poor bioavailability.
8,9
 
 Previously, polysubstituted quinolines (abbreviated as PQs) were synthesized in Hua’s 
laboratory by derivatizing the C-8 amino function of 6-methoxy-4-methyl-5-(3-
(trifluoromethyl)phenoxy)quinolin-8-amine,
10
 to study their anticancer activities.
11
 Among the 
synthesized PQs: N-(3-aminopropyl)-6-methoxy-4-methyl-5-(3-(trifluormethyl)phenoxy) 
quinolin-8-amine (PQ1), N-(furan-2-ylmethyl)-6-methoxy-4-methyl)-5-(3-(trifluoromethyl) 
phenoxy)quinolin-8-amine (PQ11), and 6-methoxy-4-methyl-N-(quinolin-4-ylmethyl)-5-(3-
(trifluoromethyl)phenoxy)quinolin-8-amine (PQ15) were found to have anti-breast cancer 
activities.
11,12
 For example, PQ1 and PQ11 were found to attenuate xenograft breast cancer 
tumor growth.
13,14
 Combinational treatment of PQ1 and tamoxifen, an antiestrogen compound 
used for the prevention of some types of breast cancer in humans, was found to lower the 
effective dose of tamoxifen in T47D cells.
13
 Moreover, PQ11, an analog of PQ1, was found to 
have improved anti-breast cancer activity as compared to PQ1.
14
 The anti-cancer activities of 
PQs have been related to the enhancement of gap junction intercellular communication (GJIC) 
by restoring gap junctions and inducing apoptosis.
12-15
 
With known anticancer activities and structures closely resembling to that of several 
known PKC inhibitors including MT477, dequalinium, and chelerythrine chloride; PQs could 
also function as PKC inhibitors.  Therefore, in this chapter the inhibition of PKC 
phosphorylation by PQ1, PQ11, and PQ15 was evaluated. In this study, staurosporine,
16
 a known 
potent PKC inhibitor and 6-methoxy-4-methyl-N-(thiophen-2-ylmethyl)-5-(3-
(trifluoromethyl)phenoxy)quinolin-8-amine (PQ10) were used as positive and negative 
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compound, respectively. The structures of PQ1, PQ10, PQ11, PQ15, and staurosporine are 
highlighted in Figure 8. 
 
 
Figure 8: Structure of PQ1, PQ10, PQ11, PQ15, and staurosporine. 
  
2.2 Background 
PKCs are known to have at least twelve isozymes and on the basis of their mode of 
activation and similarities in amino acid sequences are grouped under three subfamilies: classical 
PKCs (cPKC: PKCα, PKCβI, PKCβII, and  PKC) are activated by calcium, diacylglycerol 
(DAG) and phosphatidylserine (PS); novel PKCs (nPKC: PKCδ, PKCε, PKCη, PKCθ and 
PKCµ) are activated by DAG and PS but are insensitive towards calcium; and atypical PKCs 
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(aPKC; PKCζ and PK) are insensitive towards both calcium and DAG but can be activated by 
3-phosphoinositides (PIP3).
9,17,18
  
The single polypeptide chain of PKC is composed of an N-terminal regulatory domain (~ 
20 - 40 kDa) linked to a highly conserved C-terminal catalytic domain (~ 45 kDa) by a 
proteolytically labile hinge region (V3) as shown in Figure 9.
19
 The regulatory domain in PKCs, 
consisting of C1 and C2 regions is diverse and on the basis of this domain PKC isozymes are 
classified into three subfamilies as mentioned above. The catalytic domain, consisting of C3 and 
C4 regions is highly conserved among the isozymes. In classical PKCs (cPKCs), C1 region 
contains two duplicated cysteine rich zinc finger motifs located towards the N-terminal and 
functions as a DAG or PS binding site, C2 region contains the recognition site for acidic lipids 
and calcium binding, and C3 and C4 regions are the ATP and substrate binding sites, 
respectively.
19-21
 Novel PKCs (nPKCs) also have similar C1, C2, C3 and C4 regions; however, 
the C2 region lacks calcium binding sites and is located towards the N-terminal as shown in 
Figure 9.
19,20
 Atypical PKCs (aPKCs) differ from the classical and novel PKCs by having 
structurally different C1 region as well as lacking functional C2 region.
19,20
 The C1 region in all 
the isozymes is preceded by a pseudosubstrate that resembles a PKC substrate but contains 
alanine and not serine or threonine in the phosphoacceptor site.
22
 In the absence of activators, the 
pseudosubstrate binds to the substrate binding site of C4 region and keeps the enzyme in 
autoinhibitory (inactive) state.
23
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Figure 9: Schematic representation showing the conserved regions (C1 - C4) and variable 
regions (V1 - V5) in all three classes of PKC ioszymes.
19
  
 
2.2.1 PKC as a target in cancer therapy 
There is a plethora of literatures in which PKCs have been related to cancer. The first 
ground breaking evidence was published in the early 1980s that identified PKC as a receptor for 
phorbol esters, natural tumor-promoting compounds, and highlighted PKC as one of the most 
intensively studied enzyme in anticancer research.
7,24
 Phorbol esters have been previously linked 
to promote the formation of skin tumors on mice treated with mutagenic agent.   
PKCs have wide range of downstream signaling pathways and many of them are 
unknown. The most important downstream signaling pathway activated by PKC is the MEK-
ERK, and the other probable cancer related downstream targets are glycogen syntheses kinase-3 
beta (GSK-3β), nuclear factor kappa beta (NfκB), P-glycoprotein, etc.8,9  PKCα is known to 
activate mitogen activated protein kinase kinase kinase (MAP-KKK or Raf1), a serine/threonine 
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kinase by phosphorylation which in turn activates mitogen activated protein kinase kinase 
(MAP-KK; MEK1 and 2). The activated MEK1/2 further activates mitogen activated protein 
kinase (MAP-K; ERK 1 and 2) by phosphorylation. Finally, ERK phosphorylates several 
downstream proteins resulting in the transcription of genes involved in cell proliferation.
8
  
The expression level and function of various PKC isozymes during cancer progression 
are found to vary depending on the cell and cancer type; furthermore, the PKC isozymes 
substrate-overlapping specificities have made it difficult to pin point functions of individual 
isozymes. For example, PKCα may act as tumor promoter or as a tumor suppressor: down-
regulation of PKCα has been demonstrated in basal cell carcinoma and colon cancers,25,26 up- or 
down-regulation of PKCα has been described in hematological malignancies,27 and up-regulation 
of PKCα has been found in prostate,28 endometrial, and high-grade urinary cancer.29 Similarly, 
PKCβ expression is found to be upregulated in prostrate28 and colon cancers30 and 
downregulated in bladder cancers.
31
 However, PKCδ activity in many cases is linked to induce 
apoptosis, probably through the release of mitochondrial cytochrome c and increase in the 
expression and stability of p53 (tumor suppressor), pro-apoptotic signals as a result of PKC δ 
activation.
32-34
 In general, majority of the studies have demonstrated that increased PKCα/β 
expressions is associated with increased motility, invasion, anti-apoptotic activity, and drug 
resistance in cancer cells; the effect is reversed by inhibiting PKCs activities.
9
 Importantly, only 
few cases of mutations have been reported in PKC which might aid in the designing of 
nonresistant anticancer drugs by targeting a specific isozyme culprit in the process.
18
 Since many 
studies have linked PKC during cancer progression, therapies targeting PKC or specific PKC 
isozyme could be effective in the cure of cancers.
8,9,35
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2.2.2 PKC and breast cancer 
Breast cancer, a heterogeneous disease, is one of the most common cancers in women. 
Breast cancer comprises of about 22.9% of all cancers diagnosed in women and is a leading 
cause of women deaths worldwide.
36
 Less than 10% of the breast cancers have been related to be 
hereditary and are linked with mutation of tumor suppressor genes such as BRCA1 and BRCA2, 
whereas majority of breast cancers develop sporadically with the risk factors that include age, 
lifestyle, hormonal exposure, and environmental factors like pollution.
37
 Estrogen is a major 
steroid hormone in female endocrine system and is required for the normal growth and 
development of the body. In addition, estrogen is vital for the development of secondary sexual 
character as well as in reproduction; however, high level of estrogen in the body has been linked 
to rapid cell proliferation in breast tissues leading to breast cancer.
38
  
Increase in the PKC level is correlated to the increased resistance and metastatic potential 
of human breast cancer cells.
39
 In a study conducted among nine patients having breast cancer, 
the PKC expression was found to be significantly higher in the human breast cancer tumor cells 
as compared to the normal breast tissues of the same patients.
40
 PKC expression was found to be 
significantly higher in several estrogen receptor negative (ER
-
) human breast cancer cells as 
compared to estrogen receptor positive (ER
+
) human breast cancer cells which inversely 
correlates between the expression of PKC and estrogen receptors in the cancer cells.
41
 In vitro 
studies,  human breast cancer cells treated with phorbol ester downregulated PKC expression and 
inhibited cell growth; whereas, removal of phorbol ester from the medium upregulated PKC 
expression and resumed cell growth, suggesting that PKC is necessary for cell growth.
42,43
 These 
studies suggest the role of PKC as a potential targets in breast cancer therapy. 
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 2.2.3 Gap junction and cancer 
Gap junctions are transmembrane hydrophilic channels that connect the cytoplasm of 
adjacent cells and allow the passage of molecules such as water, cAMP, inositol triphosphate 
(IP3), glucose, and calcium that are smaller than 1200 Daltons.
44
  In normal cells gap junctions 
are present in very high-density clusters known as gap junctional plaques and are the only 
specializations in cell membranes for intercellular communication between adjacent cells.
45
 
Unlike normal cells that can communicate intercellularly through the gap junction, cancer cells 
lack or have defective gap junctions,
46
 and are unable to receive intercellular signals such as 
required for apoptosis thus preventing cell death.  
Gap junctions are formed when connexon of one cell docks with a connexon of the 
adjacent cell and each connexon is composed of six proteins of connexin family such as Cx43 
and Cx32.
47,48
 Most of the connexins with the exception of Cx26 are phosphoproteins and are 
phosphorylated by several kinases including mitogen-activated protein kinase (MAPK), protein 
kinase C (PKC), and protein kinase A (PKA).
47
  
  
2.2.4 Inhibition of gap junction intercellular communication by PKC 
PKCs have been related in the inhibition of gap junctional intercellular communication 
(GJIC) by inhibiting gap junctional channels.
49,50
 The inhibition of gap junctional channel is  
either induced by cell trauma such as sudden drop in pH and increase in Ca
2+
 level or 
physiological regulators like connexin phosphorylation.
51
 The higher the expression of 
phosphorylated form of connexin, the lower is gap junctional intercellular communication 
(GJIC). Phosphorylation of connexin mostly occurs on the serine residues of the C-terminal.
52
 
Many studies suggest the phosphorylation of Cx43 through PKC dependent pathways. Mutation 
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of Ser-368 in Cx43 partially prevented the decrease in intercellular gap junctional 
communication (CJIC) when treated with PKC in the presence of phorbol ester, a known 
activator of PKC, indicating Ser-368 as a major site for PKC phosphorylation.
53,54
  
Restoration of gap junction in cancer cells can allow the access of small anticancer drugs 
as well as apoptosis signals deep into the cancer tissues causing cells death. Inhibition of PKC 
might be crucial in restoring gap junctions, enhancing gap junctional intercellular 
communication and inducing apoptosis, leading to the possible treatment of cancer. Substituted 
quinolines (PQs) are known to inhibit PKC phosphorylation of Cx43 by disrupting the 
interactions between Cx43 and Nedd4, an E3 ubiquitin ligase, resulting in the maintenance of 
gap junctions.
12
 The structural similarities between PQs and several known PKC inhibitors like 
MT477, chelerythrine chloride, and dequalinium in having common quinoline moiety and H7 in 
having closely related isoquinoline moiety might be linked to the PKC inhibition properties of 
PQs. The structures of MT477, dequalinium, H7, chelerythrine chloride, and other known PKC 
inhibitors are highlighted in Figure 10. 
 
2.2.5 PKC inhibitors and cancer 
The role of PKC in cancer supports the notion that it could be potential therapeutic target 
in treating cancers. Several PKC inhibitors are known and some are currently employed in 
human clinical trials either as a single agent or in combination with other anti-cancer drugs. 
Approaches to inhibit PKC by small molecules are based on their binding to catalytic domain 
(ATP binding site) or regulatory domain (diacylglycerol or calcium binding site) of PKC. Known 
PKC inhibitors including safingol, calphostin C, miltefosine, bryostatin 1, curcumin, 
staurosporine and its synthetic analogs (midostaurin (PKC412), Go6850, Ro318220, Ro320432, 
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enzastaurin (LY317615), sotrastaurin (AEBO71), ruboxistaurin (LY333531), and UCN-01 (7-
hydroxystaurosporine)), tamoxifen, dequalinium, MT477, H7, chelerythrine chloride, ingenol-3-
angelate, and sangivamycin are highlighted in Figure 10. 
Sphingosine, a sphingolipid, is a potent and selective inhibitor of PKC and acts on the 
regulatory domain of PKC.
55
 Safingol, a saturated homologue of sphingosine, was the first PKC 
inhibitor to enter clinical trial in combination with doxorubicin.
56
 It has entered phase I clinical 
trial in combination with cisplatin for the treatment of advanced solid tumors.
57
  
Calphostin C, a perylenequinone, is a natural product derived from fungus Cladosporium 
cladosporioides and is a potent and highly selective inhibitor of PKC showing preference over 
cAMP-dependent protein kinase and tyrosine-specific protein kinase.
58
  Calphostin C has been 
found to induce apoptosis in broad spectrum of cancer cell lines;
59
 however, its use has been 
limited to preclinical studies only.  
Miltefosine, an alkylphosphocholine, has shown antitumor activities that might be due to 
its ability to inhibit PKC. Phase II clinical study of miltefosine in topical treatment to cutaneous 
breast cancer metastases has showed some activity with little systemic toxicity.
60
  
Bryostatin 1 is a macrocyclic lactone isolated from Bugula neritina, a marine 
bryozoans.
61
 The short-term exposure to bryostatin 1 is found to activate cPKC and nPKC, 
whereas the long-term exposure inhibits PKC activity.
62
 Phase II studies of bryostatin 1 in 
combination with paclitaxel has shown enhanced response of paclitaxel in advanced esophageal 
and gastroesophageal junction adenocarcinoma and in advanced esophageal as gastroesophageal 
junction cancer.
63,64
 Moreover, combination of bryostatin 1 with vincristine in phase II studies 
was effective in patients with aggressive B-cell non-Hodgkin lymphoma.
65
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Figure 10: Structures of known PKC inhibitors. 
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Curcumin, commonly known as turmeric and used for yellow coloration in curry, is a 
natural polyphenol derived from the plant Curcuma longa and a potent inhibitor of PKC.
66
 Anti-
tumor activities of curcumin against a broad spectrum of cancers have been investigated in 
number of preclinical studies.
35
 Phase I and phase II clinical studies has highlighted curcumin as 
a safe compound with possible therapeutic efficacy.
35
  
Chelerythrine chloride, a benzophenanthridine alkaloid derived from the plant 
Chelidonium majus, is a cell-permeable inhibitor of protein kinase C and do not inhibit protein 
tyrosine kinase, cAMP-dependent protein kinase, or calcium/calmodulin-dependent protein 
kinase.
67
 Chelerythine chloride is also known to activate MAPK pathways, independent of PKC 
inhibition and inhibit binding of BclXL to Bak or Bad proteins stimulating apoptosis.
68
 
Ingenol-3-angelate (Ing3A), extracted from Euphorbia peplus, is currently in phase III 
clinical trials for treating actinic keratosis and phase II for non-melanoma skin cancer.
69,70
 H7, an 
isoquinoline sulphonamide, is one of the early used ATP site binding inhibitor of PKC and also 
inhibits cAMP- and cGMP-dependent protein kinases.
71,72
 Rottlerin, a natural product derived 
from Mallotus philippinensis, is a selective inhibitor of PKCδ showing preference over other 
cPKCs and nPKCs; however, it is also known to inhibit PKA and calmodulin kinase III.
73,74
 
MT477, a novel thiopyranol[2,3-c]quinoline, is known to have activity against PKC isozymes 
and found to preferentially inhibit the proliferation of K-ras-mutated carcinoma as compared to 
non-Ras-mutated carcinoma.
75
  In non-Ras- mutated cancer, MT477 is found to be a selective  
inhibitor of PKCα showing preference over PKCβI, PKCβII, and PKCγ isozymes.76 
Staurosporine, a natural product isolated from bacterium Streptomyces staurosporeus  is a 
potent PKC inhibitor consisting of a sugar residue linked to a planar bis-indole carbazole.
77
 It is 
the first reported PKC inhibitor that acts on the ATP binding site of the catalytic domain of PKC. 
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Lack of specificity of staurosporine towards kinases makes it highly toxic and has precluded it 
from clinical use. However, analogs of staurosporine including, midostaurin (PKC412) and 
UCN01 are more potent and specific inhibitors of PKC.  
Midostaurin, an N-benzoylated staurosporine analog, was the first PKC inhibitor to be 
used in oncology clinical trials and known to be more selective than staurosporine towards PKCs 
inhibitions; however it also inhibits other kinases like inert domain receptor KDR, VEGF-R2, 
PDGF, and c-kit.
78
 Phase I studies of midostaurin in combinations with 5-fluorouracil, paclitaxel 
and carboplatin, and gemcitabine and cisplatin has highlighted that midostaurin can be safely 
used for treating certain cancers.
79,80
 However, midostaurin failed to demonstrate significant 
clinical activities in phase II trials. 
UCN01, an analog of staurosporine preferably suppresses the activities of cPKCs as 
compared to other PKC isozymes.
81
 UCN01 is in clinical trials for leukemia, non-small cell lung 
cancer (NSCLC) and lymphoma.
35
   
Enzastaurin (LY317615) is a potent inhibitor of PKCβ.82 Enzastaurin was found to be 
effective in phase I and II trials in the patient with recurrent high-grade gliomas.
83
 Phase III 
study conducted to compare the efficacy of enzastaurin with lomustine in the treatment of patient 
with recurrent glioblastoma showed its better efficacy towards hematological profile; however, 
was less effective than lomustine.
84
  
Sotrastaurin (AEB071) is a potent and selective inhibitor of cPKCs and nPKCs and has 
found to have high immunodilatory effect via inhibition of early T cell activation.
85
 It is currently 
in phase II clinical trial for the prevention of solid organ allograft rejection.
85
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Since PQs are known to have anticancer activities with their structures closely resembling 
to that of several PKC inhibitors including MT477, dequalinium, chelerythrine chloride, and H7; 
therefore, PQs might also function as PKC inhibitors.  
 
2.3 PKC inhibition by substituted quinolines (PQs) 
 2.3.1 Methods and materials 
The PepTag® non-radioactive PKC assay kit (catalog # V5330) was purchased from 
Promega and PKC inhibition studies were carried out following the protocol published by 
Promega (technical bulletin #132) with minor modifications.  
Protein Kinase C phosphorylation is determined by the use of fluorescent PepTag “C1 
peptide” substrate consisting of eleven amino acids residues (amino acids sequence of C1 
peptide; proline – leucine – serine – arganine – threonine – leucine – serine – valine – alanine – 
alanine – lysine). A dye molecule attached to the C1 peptide substrate imparts bright pink 
fluorescence to the peptide. At pH = 7.4, pH of the reaction, the C1 peptide in the 
nonphosphorylated state has a net +1 charge which changes to net -1 charge on PKC 
phosphorylation as illustrated in Figure 11.
86
 In spite of having two serines (Ser-3, and Ser-7) 
and one threonine (Thr-9) residues in the amino acid sequence of C1 peptide only Ser-7 is 
phosphorylated; Ser-3, and Thr-9 are not typically phosphorylated due to steric hindrance.
87
  The 
phosphorylated and nonphosphorylated C1 peptides can be separated by agarose gel 
electrophoresis, a method used to separate oppositely charged peptides or proteins (Figure 12). 
The use of non-radioactive assay is more rapid and convenient than the one that determines PKC 
activity by measuring the transfer of radioactive phosphate (
32
PO4
2-
) group from the enzyme to 
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the substrate peptides or proteins.
88
 During electrophoresis the nonphosphorylated peptide (+Ve 
charged) moves towards the negatively charged anode whereas the phosphorylated peptide (-Ve 
charged) moves toward the positively charged cathode and get separated as shown in Figure 12.  
 
 
 
Figure 11: Amino acid sequence of C1 peptide and the change in net charge (+1) of 
nonphosphorylated peptide to the net charge of (-1) of phosphorylated peptide at pH = 7.4. 
 
The phosphorylated and nonphosphorylated bands were visualized under UV light and 
the fluorescence intensities (pixel intensities) of the bands were quantified using Kodak Gel 
Logic 1500 Digital Imaging System and Imagequant 5.2 software; facilities provided by Dr. 
77 
 
Govindsamy Vediyappan laboratory, in the Division of Biology, Kansas State University. The 
ratio of the phosphorylated band intensity to the sum of the phosphorylated and 
nonphosphorylated band intensities was used as a measure of percentage phosphorylation of C1 
peptide.
89
  
 PepTag® assay kit for non-radioactive detection of protein kinase C consists of the 
following: PepTag® C1 peptide (0.4µg/µL in water), conjugated to a fluorescent molecule; 
PepTag® PKC reaction buffer having 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), pH 7.4, 6.5 mM CaCl2, 5 mM dithiothreitol (DTT), 50 mM MgCl2, and 5mM 
adenosine triphosphate (ATP); PKC (25 µg/mL) having 20 mM 
tris(hydroxymethyl)aminomethane hydrochloride (C(CH2OH)3NH2. HCl; Tris-HCl), pH 7.4, 2 
mM ethylenediaminetetraacetic acid (EDTA), 1mM DTT, 10 mM K3PO4, 0.05% Triton® X-100 
and 50% glycerol; gel solubilization solution (composition not supplied); and PKC activator 
solution having 1 mg/mL of phosphatidylserine (PS) in water; and peptide protection solution. 
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Figure 12: Schematic diagram showing the phosphorylation of C1 peptide by PKC and the 
separation of phosphorylated and nonphosphorylated C1 peptide by agarose gel electrophoresis. 
In the above figure, P = proline, L = leucine, S = serine, R = arganine, T = threonine, V = valine, 
A = alanine, and K = lysine.  
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2.3.2 Experimental  
 2.3.2.1 PKC inhibition studies 
The inhibition of PKC phosphorylation was carried out following the protocol supplied 
by Promega (technical bulletin #132) with minor modifications. The negative control in the 
experiment consisted of C1peptide but without PKC and PKC inhibitor (staurosporine or PQs); 
the positive control consisted of both C1 peptide and PKC but without PKC inhibitor; and the 
other experiments consisted of C1 peptide, PKC, and PKC inhibitor in varying concentrations. 
The inhibition of PKC phosphorylation by staurosporine or PQs in various concentrations was 
demonstrated by the decrease in the intensities of their respective phosphorylated bands as 
compared to the phosphorylated band of the positive control.  
 
2.3.2.2 Preparation of agarose gel 
 To a solution of 50 mL of 50 mM Tris-HCl (pH 8.0) buffer was added 0.4 g of agarose,  
heated to boiling in a microwave till all of the agarose dissolved, cooled to about 60
o
C, and 
slowly added into a gel tray having required number of comb(s) placed in a mini horizontal 
electrophoresis apparatus.
90
 Any bubbles formed in the solution were carefully removed with a 
pipette tip. On standing for 20 minutes the agarose solution solidified to a gel. Careful removal 
of the comb(s) gave desired number of wells for sample loading. The gel was covered with 50 
mM Tris-HCl solution (pH 8.0) as a running buffer.  
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2.3.2.3 Preparation of reaction solutions 
Each experiment (PKC inhibition studies) generally comprised of 7 reactions; one 
negative control, one positive control, and the remaining five with PKC inhibitor (staurosporine 
or PQs) in different concentrations. The procedure was based on Promega technical bulletin 
(#132) and is mentioned below: 
1. Eight 1-mL microcentrifuge tubes were taken and labeled as mixture, negative control, 
positive control, and the remaining five as required PKC inhibitor concentrations. 
2. In negative control, 6 µL of deionized water was added, whereas in positive control 3 µL 
(15 ng) of diluted PKC (PKC dilution solution comprises of 100 µg/mL of bovine serum 
albumin (BSA) and 0.05% of Triton® X-100) and 3 µL of deionized water or 1:2 mixture of 
DMSO and deionized water (based on the solvent used for dissolving PKC inhibitors) was 
added.  
3. In other five reactions, 3 µL (15 ng) of diluted PKC and 3 µL of drug solution of required 
concentration (each tube had different concentration of drug) in deionized water or 1:2 
mixture of DMSO and deionized water were added. The reactions mentioned in points 2 and 
3 of this section were then incubated at room temperature for 5 minutes. 
4. In a tube labeled as mixture, 17.5 µL of PKC reaction buffer, 17.5 µL of PKC activator 
solution, 3.5 µL peptide protection solution, and 14 µL (5.6 µg) of C1 peptide were added at 
0
o
C and incubated for 2 minutes in water bath maintained at 30
o
C. From the tube 7.5 µL of 
the solution were added to each tube labeled as negative control, positive control, and five 
reactions with varying drug concentrations. Each tube had 0.8 µg of C1 peptide in the total 
volume of 13.5 µL.  
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5. Negative control, positive control, and other five reactions with drug were incubated for 45 
minutes in water bath maintained at 30
o
C.   
6. The reaction was stopped by deactivating PKC enzyme by placing the tubes in boiling water 
for 10 minutes. 
7. The tubes were then allowed to cool at room temperature and 0.5 µL of 80% glycerol was 
added to each tubes. The samples were now ready to be loaded into the agarose gel for the 
separation of phosphorylated and nonphosphorylated peptides by horizontal gel 
electrophoresis. 
  
2.3.2.4 Separation of phosphorylated and nonphosphorylated peptides by electrophoresis 
  Electrophoresis is a process of separation of molecules having different charge or size by 
the application of electric field. The samples from each tube (as described in section 2.3.2.3) 
were loaded in separate wells in the agarose gel placed in a horizontal gel electrophoresis 
chamber and electrophoresis was carried for 30 minutes at 100 V. As the net +1 charge in a 
nonphosphorylated C1 peptide is changed to a net -1 charge after phosphorylation,
86
 on 
electrophoresis the nonphosphorylated peptides (+Ve charged) move towards the negatively 
charged electrode (anode) and the phosphorylated peptides (-Ve charged) move towards the 
positively charged electrode (cathode) and separate from each other.  
 
2.3.2.5 Quantification of phosphorylated and nonphosphorylated bands 
The gel after electrophoresis was removed from the electrophoresis chamber, 
photographed under UV by Kodak Gel Logic 1500 Digital Imaging System,
91
 and quantification 
of both phosphorylated and nonphosphorylated bands were carried out by Imagequant 5.2 
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software (Molecular Dynamics/Amersham Biosciences),
92
 using the facilities in Dr. 
Govindasamy Vediyappan laboratory, in the Division of Biology, Kansas State University. 
Quantification of the bands by the use of Imagequant 5.2 software is referred as photoimaging 
analysis in this chapter. For the quantification, the tiff image file of the gel was inverted (bands 
are black and background is white, opposite to the normal picture) and background correction 
was done to minimize noise. The obtained volumes of the bands (pixel intensities) were then 
used to determine the amounts of phosphorylated and non phosphorylated C1 peptide which is 
discussed in details in the following section. The accuracy of photoimaging analysis was tested 
by comparing the results with that of spectrofluorometric analysis, and was found to be similar. 
Thus the more convenient photoimaging analysis was carried out for the quantification of 
phosphorylated and nonphosphorylated C1 peptides in all performed experiments. 
For spectrofluorometric analysis the bands were carefully incised with a clean and sharp 
razor and placed in a separate (labeled) 1 mL graduated micro centrifuge tubes. The gels in the 
tubes were heated on boiling water until they melted. After adjusting the volume in each tube to 
250 µL by the addition of deionized water (wherever necessary), 175 µL of each solutions were 
transferred to different tubes containing 75 µL of gel solubilization solution, 50 µL of glacial 
acetic acid, and 400 µL of deionized water, and vortexed. The solutions were then ready for 
spectrofluorometric analysis. The maximum intensities of the phosphorylated bands of positive 
control and reactions with different PKC inhibitor (PQs or staurosporine) concentration were 
compared from their respective emission spectra (max = 592 nm; obtained with the excitation 
wavelength of 568 nm). The difference in the phosphorylation of peptide in the absence and 
presence of PKC inhibitors was calculated and inhibitions of PKC phosphorylation by the 
inhibitors were determined.  
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To minimize the effect of diffusion and overflowing of the lanes during the sample 
loading during gel electrophoresis, the sum of intensities or volumes of both phosphorylated and 
nonphosphorylated bands of each reaction were taken and considered to be the contribution of 
0.8 µg of peptide that was initially added in each reaction. From this value the corrected amount 
of peptide phosphorylation and percentage of peptide phosphorylation were determined as 
mentioned in the second last and last columns of Tables 1, 2, and 3.  
The correlation studies between the peptide phosphorylation and (a) the concentration of 
PKC (0 - 40 ng) and (b) time (15 to 60 minutes) were carried out before preceding the 
phosphorylation inhibition studies. 
  
2.4 Results and discussions 
 2.4.1 Studies of the correlation between peptide phosphorylation verse                        
(1) concentrations of PKC, and (2) time 
 
Correlations between peptide phosphorylation verse (a) concentration of PKC, and (b) 
time were established before setting parameters for the experiments. 
  
 2.4.1.1 Correlation between peptide phosphorylation verses concentrations of PKC 
The phosphorylation of the substrate peptide (C1 peptide) increased linearly with the 
increase in the amount of PKC (0 - 40 ng) as determined by both spectrofluorometric (bottom 
left of Figure 13) and photoimaging analysis (bottom right of Figure 13). The percentage of C1 
peptide phosphorylation with varying concentrations of PKC, as measured by both 
spectrofluorometric and photoimaging methods, are highlighted in Table 1 and 2, respectively. 
The amounts of PKC required to phosphorylate 50 % of the C1 peptide were found to be 29 ng 
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and 30 ng from spectrofluorometric and photoimaging analysis, respectively. Results obtained 
from both methods were similar with an average difference of 4%. The use of 15 ng of PKC 
produced about 30% of C1 peptide phosphorylation; therefore, 15 ng of PKC was used in the 
following experiments to study the inhibition of PKC phosphorylation by staurosporine and PQs.  
 
Table 1: Percentage phosphorylation of C1 peptide with varying amounts of PKC (0, 5, 15, 20, 
30, and 40 ng) as determined by spectrofluorometric analysis 
 
Amount of 
PKC (ng) 
Maximum Intensity 
A+B 
(Intensity due 
to 0.8 µg of 
C1 peptide) 
Corrected 
amount of 
peptide 
phosphorylated  
(A’, µg) 
(0.8× A/(A+B) 
% Peptide 
phosphorylation 
(A’ × 100/ 0.8) 
% 
Phosphorylated 
peptide (A) 
Non 
phosphorylated 
peptide (B) 
0 0 3014204 3014204 0 0 
5 207960 2719242 2927202 0.057 7.1 
15 978600 2508340 3486940 0.225 28.1 
20 1199304 1960410 3159714 0.304 38 
30 1937402 1725586 3662988 0.423 52.9 
40 2246314 1444880 3491194 0.514 64.3 
 
Table 2: Percentage phosphorylation of C1 peptide with varying amounts of PKC (0, 5, 15, 20, 
30, and 40 ng) as determined by photoimaging analysis 
 
Amount of 
PKC (ng) 
Volume (Pixel Intensity) 
A+B 
(Intensity due 
to 0.8 µg of 
C1 peptide) 
Corrected 
amount of 
peptide 
phosphorylated  
(A’, µg) 
(0.8× A/(A+B) 
% Peptide 
phosphorylation 
(A’ × 100/ 0.8) 
% 
Phosphorylated 
peptide (A) 
Non 
phosphorylated 
peptide (B) 
0 0 129513 129513 0 0 
5 17595 133628 151223 0.093 11.63 
15 80358 148940 229298 0.280 35 
20 91876 134506 226382 0.325 40.58 
30 110573 104745 215318 0.411 51.35 
40 140443 94755 235198 0.478 60 
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Figure 13: Gel image and graphs of C1 peptide phosphorylation with the amount of PKC. The 
amount of PKC used ranged from 0 - 40 ng (top). The negative control refers to no PKC (0 
ng).The linear correlation of peptide phosphorylation vs. amount of PKC in nanograms (ng) was 
established by the spectrofluorometric (bottom left) and photoimaging (bottom right) methods. 
The results obtained in both cases were similar with an average difference of ~ 4%.  
 
 
2.4.1.2 Correlation between the changes in peptide phosphorylation over time (15 - 60 min)  
 The percentage of peptide phosphorylation with respect to time was studied to find out 
the appropriate reaction time for the preceding experiments. For this 15 ng of PKC and 0.8 µg of 
C1 peptide were used in each reaction (four reactions) and the first, second, third, and fourth 
reaction were stopped at 15, 30, 45, and 60 minutes respectively by deactivating PKC enzyme by 
placing the reaction on boiling water for 10 minutes. The reactions were then loaded into the 
sample loading wells in agarose gel for the separation of both phosphorylated and non 
phosphorylated peptides by horizontal gel electrophoresis. Percentage of C1 peptide 
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phosphorylation over time is summarized in Table 3, whereas the gel image and the 
corresponding graph are highlighted in Figure 14.  
 
Table 3: Percentage phosphorylation of C1 peptide with varying time (15 - 60 minutes) 
Time 
(minutes) 
Volume (Pixel Intensity) 
A+B 
(Intensity due 
to 0.8 µg of 
C1 peptide) 
Corrected 
amount of 
peptide 
phosphorylated  
(A’, µg) 
(0.8× A/(A+B) 
% Peptide 
phosphorylation 
(A’ × 100/ 0.8) 
% 
Phosphorylated 
peptide (A) 
Non 
phosphorylated 
peptide (B) 
0 0 452529 452529 0 0 
15 212081 430388 642469 0.264 33 
30 182748 321058 503806 0.290 36.3 
45 265429 412429 677858 0.313 39.2 
60 281580 360734 642314 0.350 43.8 
 
 
Figure 14: Gel image and linear correlation between percentage phosphorylation of C1 peptide 
catalyzed by PKC (15 ng) over time (15 - 60 min). Diffusion on loading 30 min reaction caused 
the decrease in the pixel intensities of both phosphorylated and nonphosphorylated bands which 
was corrected as shown in Table 3. 
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Percentage phosphorylation of C1 peptide with PKC showed a linear correlation with 
time within the experimental range from 15 to 60 minutes as shown in Figure 14. For each 
reaction the incubation time could be chosen between 15 to 60 minutes; however, 45 minutes 
incubation time was chosen for the phosphorylation experiments. Longer incubation time (> 
hour) was avoided since PKC is labile at room temperature. 
 
2.4.2 Inhibition of PKC phosphorylation by staurosporine 
Staurosporine is a natural product isolated from bacterium Streptomyces staurosporeus 
by Omura et al in 1977.
77
 Staurosporine molecule consists of a sugar residue, with a unique 
stereochemical arrangement, linked to a planar bis-indole carbazole unit.  
Initially, staurosporine was found to have biological activities ranging from anti-fungal to 
anti-hypertensive; however, elaborated studies highlighted staurosporine as a potent, but not 
selective inhibitor of various protein kinases including PKC with IC50 values in nanomolar 
range.
93,94
 The higher affinity of staurosporine towards the adenosine triphosphate (ATP) binding 
site on the catalytic domain of PKC prevents the binding of ATP to the PKC, thus inhibiting 
PKC.
94
 Lack of specificity of staurosporine towards kinases makes it highly toxic and has 
precluded it from clinical use. Staurosporine has an ability to drive virtually all mammalian cells 
to apoptosis; therefore, the role of staurosporine is virtually restricted in research to induce 
apoptosis.  
Staurosporine was used as a positive compound to study the inhibition of PKC 
phosphorylation. The inhibition of PKC phosphorylation was carried out as per the protocol 
supplied by Promega and as explained in section 2.3 of this chapter. The gel image, percentage 
of C1 peptide phosphorylation catalyzed by PKC, and the percentage of PKC inhibition in the 
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absence and presence of various concentrations of staurosporine is highlighted in Figure 15. IC50 
value of staurosporine towards the inhibition of PKC phosphorylation was found to be 33 nM 
(Figure 20); however, IC50 value of 22 nM has been previously reported by Wilkinson et al.
95
 
 
 
Figure 15: Gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and 
percentage inhibition of PKC phosphorylation in the presence and absence of staurosporine. All 
the reactions have 0.8 µg of C1 peptide and 15 ng of PKC. In the negative and positive control 
there is no staurosporine whereas other reactions have different concentrations of staurosporine 
as mentioned in the graphs. The graphs are provided with (±) standard error obtained from three 
separate experiments.    
 
2.4.3 Inhibition of PKC phosphorylation by PQs (PQ1, PQ10, PQ11, and PQ15) 
 Polysubstituted quinolines, abbreviated as PQ’s, were synthesized by Jianyu Lu, in Hua’s 
laboratory, following the literature procedure previously reported.
11
 Structures of PQ compounds 
examined for  the inhibition of PKC phosphorylation, in this chapter, are listed in previous 
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Figure 8. These PQ compounds are known to have anti-breast cancer activities. Among the PQ 
compounds, PQ1 and PQ11 have IC50 values of 119 nM and 15.6 nM in T47D cancer cells and 
are potential compounds for developing anticancer drugs.
11
 PQ10 was less active against T47D 
cell line with IC50 value of 3.7 µM.
11
  
 N-(3-Aminopropyl)-6-methoxy-4-methyl-5-(3-(trifluormethyl)phenoxy)quinolin-8-amine 
(PQ1), a potent anticancer drug was found to induce apoptosis in cancer cells by enhancing or 
restoring gap junction intercellular communication (GJIC); moreover, PQ1 had no effect on gap 
junction intercellular communication (GJIC) in normal cells.
13
 PQ1 was found to inhibit the 
phosphorylation of Cx43, gap junction protein and increased the expression of active caspase-3, 
suggesting its role as apoptosis inducing agent.
13
 In vivo studies indicated that PQ1 suppressed 
the xenograft tumor growth of T47D cells in nude mice.
13
 Combinational treatment of PQ1 and 
tamoxifen lowered the effective dose of tamoxifen in T47D cells.
13
 
 Since PKC is linked in the catalysis of phosphorylation of gap junction protein Cx43, the 
effect of PQ1 on PKC phosphorylation was studied. The PKC phosphorylation inhibition studies 
highlighted PQ1 as a potent PKC inhibitor with IC50 value of 35 nM (Figure 20), and its activity 
was comparable to that of staurosporine (IC50 value of 33 nM) as measured in the previous 
section.  The gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and 
percentage inhibition of PKC in the presence and absence of PQ1 is highlighted in Figure 16. 
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Figure 16: Gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and 
percentage inhibition of PKC phosphorylation in the absence and presence of PQ1. All the 
reactions have 0.8 µg of C1 peptide and 15 ng of PKC. In negative and positive control there is 
no PQ1 and others have varying concentrations of PQ1 as indicated in the graphs. The graphs are 
provided with (±) standard error obtained from three separate experiments. 
  
 N-(Furan-2-ylmethyl)-6-methoxy-4-methyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-
amine (PQ11) was found to have much improved anticancer activities than PQ1.
14
 PQ11 was 
found to increase the expression of Cx43, a gap junctional protein, in T47D cells enhancing 
GJIC in the cells.
14
 PQ11 at 500 nM was known to enhance the GJIC by 1.7 and 16 folds as 
compared to PQ1 treated (under identical conditions) and nontreated T47D cells, respectively.
14
 
Similarly, 100 nM of PQ11 and PQ1 inhibited the colony growth  of T47D by 66% and 50 % 
respectively.
14
 In vivo studies showed that PQ11 treated nude mice grafted with T47D tumor had 
no tumor left after 7 injections of  1 µM PQ11 in 14 days.
14
  The increase in expression of 
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caspase-9 on cancer cells treated with PQ11 was linked to the role of PQ11 in the induction of 
apoptosis.
14
 These results demonstrate the potency of PQ11 in the development of potential  
anticancer drug.
14
 The inhibition of PKC phosphorylation by PQ11 was therefore studied and the 
corresponding IC50 value was obtained as 42.3 nM, which is slightly higher than that of PQ1 as 
shown in Figure 20. The higher IC50 value of PQ11, towards PKC inhibition, as compared to 
PQ1 is surprising but may be related to the difference in their cellular targets other than PKC. 
The gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and percentage 
inhibition of PKC phosphorylation in the absence (positive control) and presence of PQ11 is 
highlighted in Figure 17. 
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Figure 17: Gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and 
inhibition of PKC phosphorylation in the presence and absence of PQ11. All the reactions have 
0.8 µg of C1 peptide and 15 ng of PKC. In the negative and positive control there is no PQ11 
and others have varying concentrations of PQ11 as indicated in the graphs. The graphs are 
provided with (±) standard error obtained from three separate experiments. 
  
 Another analog of PQ1, 6-methoxy-4-methyl-N-(quinolin-4-ylmethyl)-5-(3-
trifluoromethyl)phenoxy)quinolin-8-amine (PQ15), was also found to have anticancer activities, 
but less potent than PQ1 and PQ11.
12
 PQ15 was found to enhance gap junctional intercellular 
communication (GJIC) by inhibiting the PKC phosphorylation of Cx43, resulting in the decrease 
of cell proliferation and viability in T47D cells.
12
 Moreover, PQ15 was found to downregulate 
the expression of α-survivin, a member of the inhibitor of apoptosis (IAP) family, increasing 
apoptosis and decreasing chemoresistance in T47D cells.
12
 Alpha-survivin is overexpressed in 
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human cancer and might be associated to the prolonged life of cancer cells by increasing 
resistance to chemotherapy.
96
 The inhibition of PKC phosphorylation by PQ15 was therefore 
studied and the corresponding IC50 value of 216.3 nM was obtained, which was significantly 
higher than that of PQ1 and PQ11 as shown in Figure 20. The gel image, percentage of C1 
peptide phosphorylation catalyzed by PKC, and inhibition of PKC phosphorylation in the 
absence (positive control) and presence of PQ15 is highlighted in Figure 18.  
 
 
Figure 18: Gel image, percentage of C1 peptide phosphorylation catalyzed by PKC, and 
percentage inhibition of PKC in the absence and presence of PQ15. In the negative and positive 
control there is no PQ15 and others reactions have varying concentrations of PQ15 as indicated 
in the graphs. The graphs are provided with (±) standard error obtained from three separate 
experiments. 
 
Among the compounds examined, 6-methoxy-4-methyl-N-(thiophen-2-ylmethyl)-5-(3-
(trifluoromethyl)phenoxy)quinolin-8-amine (PQ10) did not show inhibition of PKC 
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phosphorylation within the studied concentration range of 1-20 µM. The gel image and 
percentage of C1 peptide phosphorylation by PKC in the absence (positive control) and presence 
of PQ10 in highlighted in Figure 19. 
 
Figure 19: Gel image and percentage of C1 peptide phosphorylation by PKC in the absence and 
presence of PQ10. All the reactions have 0.8 µg of C1 peptide and 15 ng of PKC. In positive 
control there is no PQ10 and others have varying concentrations of PQ10 as indicated in the bar 
graphs. PQ10 shows no inhibition of PKC phosphorylation in the range of 1-20 µM. Only one 
experiment was carried out for PQ10. 
  
The IC50 values of staurosporine, PQ1, PQ11, and PQ15 determined from PKC inhibition 
studies are summarized in Figure 20. A close structural resemblance of polysubstituted 
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quinolines (PQs) with that of several PKC inhibitors, including MT477, dequalinium, 
chelerythrine chloride, and M7 in having quinolines or isoquinoline moieties and with 
staurosporine and its analogs having closely related indole moiety might contribute to the PKC 
inhibition properties of PQs. However, the specificity of PQs towards PKC isozymes and other 
kinases has to be investigated. 
 
 
Figure 20: IC50 values of staurosporine (ST), PQ1, PQ11, and PQ15. The values have been 
derived from three separate experiments for each compound and the bars are provided with (±) 
standard error. 
 
2.5 Conclusions 
 Polysubstituted quinolines (PQs); PQ1, PQ11, and PQ15 known to have anti-breast 
cancer activities were evaluated for their role in the inhibition of PKC phosphorylation. The 
study indicated that PQ1, PQ11, and PQ15 were found to inhibit PKC phosphorylation with IC50 
values of 35, 42.3, and 216.3 nM, respectively. Moreover, PQ1 and PQ11 were found to be 
potent PKC inhibitor as comparable to staurosporine with IC50 value of 33 nM. These results 
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indicate the possibility of developing PQ1 and PQ11 as possible anticancer drugs targeting PKC. 
However, it is still not known whether PQs are isozymes specific inhibitors of PKC or may even 
target other kinases.    
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Chapter 3. Distribution of PQ1 and PQ11 in tissues of mice and 
effect of PQ1 in normal tissues 
 
3.1 Introduction 
Cancer, a broad group of more than 100 diseases characterized by the unregulated growth 
and spread of abnormal cells in the body, has been listed as one of the most important public 
health problems in today’s world. In 2008, an approximate of 12.6 million new cases of cancer 
were reported worldwide causing 7.6 million lives in the same year.
1
  In 2011, about 1.6 million 
new cases of cancer were reported in the United States resulting in 0.6 million deaths in the same 
year.
2
 In general, about 25% of all deaths in the United States is associated with cancer.
2
  In the 
United States, breast cancer is the most common cancer in women and one in every eight women 
has a chance of getting breast cancer in her life time.
2
 
Quinolines are known to have wide range of biological activities including antifungal,
3
 
antibacterial,
4
 and antimalarial.
5
 Quinolines are also found to have anticancer activities such as 
by targeting tumor hypoxia,
6,7
 inhibiting topoisomerase,
8
 inhibiting tyrosine kinase,
9
 and 
reversing multidrug resistance.
10
 For example: irinotecan and topotecan, derivatives of 
camptothecin are used in the treatment of colorectal and ovarian cancer, respectively.
11
 
Amsacrine, another anticancer drug having a quinoline motif is used in the treatment leukemia 
and lymphomas in many countries.
12
 The structures of camptothecin, irinotecan, topotecan, and 
amsacrine are highlighted in Figure 21.   
Substituted quinolines (PQs), N-(3-aminopropyl)-6-methoxy-4-methyl-5-(3-
(trifluormethyl) phenoxy)quinolin-8-amine (PQ1) and N-(furan-2-ylmethyl)-6-methoxy-4-
methyl)-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine (PQ11) are potential anticancer drugs 
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with respective IC50 value of 119 and 15.6 nM in T47D cells.
13,14
 PQ1 and PQ11 are known to 
enhance gap junctional intercellular communication (GJIC) resulting in the decrease in cell 
viability and proliferation in cancer cells.
13,15
 The enhancement in GJIC in T47D cells by PQ1 
and PQ11 is linked to the inhibition of PKC phosphorylation of Cx43, a gap junctional 
protein.
13,15,16
 The increase in gap junction activities is positively related to the increase in 
apoptosis and drug sensitivity in cancer cells.
17
 In vivo studies, PQ1 and PQ11 have 
demonstrated the attenuation of  T47D xenograft tumors in nude mice up to 100%.
13,15
 As 
discussed in chapter two of this thesis, PQ1 and PQ11 are found to be potent inhibitors of PKC 
with IC50 values of 35 and 42.3 nM, respectively.  
 
Figure 21: Structures of quinoline motif bearing anticancer drugs: camptothecin, topotecan, 
irinotecan, and amsacrine. 
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However, for a cancer drugs to be effective, they must reach the targeted tissues in the 
body in concentrations sufficient to kill the cancer cells without producing cytotoxic or adverse 
effects in normal cells. In this chapter, the time dependent distribution of PQ1 and PQ11 in 
different organs of normal C57BL/6J mice and the effect of PQ1 on the normal organs are 
discussed. These studies are essential to establish PQ1 and PQ11 as potential candidates in the 
development of gap junctional or PKC targeting anticancer drugs by finding their possible 
toxicity and locating their presence in various tissues.  
Oral gavage of PQ1 was conducted by Dr. Thu Annelise Nguyen and me, Intraperitoneal 
(IP) injection of PQ11 was done by Stephanie Shishido, and the effect of PQ1 in the normal 
tissues was studied by Ying Ding. Stephanie Shishido and Ying Ding are graduate students in 
Dr. Thu Annelise Nguyen group, College of Veterinary Medicine, Department of Diagnostic 
Medicine Pathobiology, Kansas State University. 
 
3.2 Background 
 The mode of treatment of cancer is diverse including surgery, radiation, chemotherapy, 
hormone therapy, and targeted therapy. Surgery is carried out to remove the tumor from the body 
and is very effective for curing cancer that has not spread to other parts of the body. Radiation 
therapy uses high energy radiations to kill cancer cells by damaging their DNA. Cancer cells are 
known to grow and divide rapidly and chemotherapy is the most commonly used method to treat 
cancers by using chemicals capable of killing rapidly dividing cells in the body. In hormone 
therapy, a patient is treated with drugs that either prevent the cancer cell to come in contact with 
hormones that help the cancer cells to grow or activate the production of hormones that kill 
cancer cells. Finally, in targeted therapy drugs that block the growth and spread of cancer cells 
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by targeting specific culprit molecules in tumor growth and progression are used. In general the 
combination of different methods is used for the effective treatment of cancer. 
Understanding how drugs behave in a biological system is a subject of prime importance 
in the treatment of various diseases. The circulatory system which comprises of blood and blood 
vessels is generally used to distribute drugs in several tissues in the body.  
For systemic drug administration in research, the drugs are generally administered in the 
mice through three main routes that include oral gavage, intravenous injection, and 
intraperitoneal injection. In oral gavage, the drug in the form of solution is administered directly 
into the lower esophagus or stomach by the use of feeding needle. The feeding needle has a bulb 
tip which prevents the rupture of delicate tissues during the drug administration. The maximum 
volume that can be feed by oral gavage is 10 mL/Kg body weight of the mice. 
Intraperitoneal (IP) injection of drug is one of the most frequently performed drug 
administration methods in mice. In this method the drug in the form of the solution is injected 
into the peritoneal cavity, a space that surrounds the abdominal organs. A small and thin needle 
is inserted into the abdominal cavity in the lower right quadrant to avoid the puncture of cecum 
and urinary bladder with the needle. For IP injection the volume of drug solution should not 
exceed 2 mL in an adult mouse. 
Intravenous (IV) injection is used to administer the drug solution directly in the blood 
through veins. The vein in the tail of a mouse functions in thermoregulation and dilates on the 
rise in body temperature.  Thus application of heat to the tail of the mouse causes venodilation 
making the veins easily accessible for IV administration. The maximum volume of drugs 
administration through IV should not exceed 0.5 mL in an adult mouse.  
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 The drugs administered through oral gavage and IP injections must first diffuse into the 
blood stream. The blood then transports and distributes the drugs in various tissues in the body as 
shown in Figure 22.  
 
Figure 22: Schematic representation of blood circulation in mammals. 
 
3.3 Experimental 
Substituted quinolines, PQ1 and PQ11, were obtained as described by Shi et al.
14
  Oral 
gavage of PQ1, intraperitoneal (IP) injection of PQ11, and the effect of PQ1 in the mice tissues 
were studied in Dr. Annelise Nguyen laboratory. For PQ1 studies, each group consisted of four 
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female C57BL/6J mice and the distribution of PQ1 and its effect in normal tissues were studied 
at 1 hour, 12 hours, and 24 hours after the dosage of PQ1 by oral gavage. For PQ11, each group 
consisted of six female C57BL/6J mice and the tissue distribution of PQ11 was studied at 6 
hours, 12 hours, 24 hours, and 36 hours after the dosage of PQ11 by intraperitoneal injection.     
 
3.3.1 PQ1 and PQ11 administration and tissue collection  
A dose of 25 mg/Kg (mice body weight) of PQ1 or PQ11 as their succinic acid salt 
dissolved in DMSO was administered to the mice. PQ1 was administered by oral gavage, 
whereas PQ11 was administered by IP injection. The distribution of PQ1 in the organs was 
analyzed in 1, 12, and 24 hour times from the exposure of PQ1. The animals were euthanized 
with CO2 and sacrificed by cervical dislocation. The blood was immediately collected in a 
heparin-coated 1mL syringe by cardiac puncture. Various tissues including brain, heart, liver, 
lungs, uterus, and kidneys were obtained after immediate dissection of the animal and kept in 
vials over dry ice. The blood was centrifuged to collect plasma. All the tissues and plasma 
collected were stored at -78
o
C until further analysis was carried. 
In case of PQ11, distribution of drug to the various tissues and plasma was evaluated in 6, 
12, 24, and 36 hour times of the drug exposure. Similar method as applied for PQ1 was followed 
to collect plasma and tissue samples (liver, lungs, kidney, heart, spleen, uterus, gastro intestinal 
tract, and brain) from the mice.  
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3.3.2 Extraction of PQ1 and PQ11 from organs and plasma 
Organs were weighed and cut into small pieces followed by the addition of 4 mL of 
deionized water and 10 mL of 9:1 mixture of ethyl acetate and 1-propanol.  Known volume of 
plasma samples were directly mixed with 4 mL of deionized water and 10 mL of a 9:1 mixture of 
ethyl acetate and 1-propanol.  Sodium bicarbonate (10 mg) was added to the tissue or plasma 
solutions and were sonicated for 40 minutes and 10 minutes, respectively. The organic layer was 
separated from a separatory funnel.  The aqueous layer was extracted twice with 10 mL of a 9:1 
mixture of ethyl acetate and 1-propanol.  The organic layers were combined, washed with 5 mL 
of brine, dried over anhydrous MgSO4, and concentrated to dryness on a rotary evaporator.  The 
residue was diluted with 1 mL of 1-propanol and filtered through a 0.2 µm filter disc (PTFE 0.2 
µm, Fisherbrand) and analyzed using HPLC and mass spectrometry as described below. 
 
3.3.3 Quantification of PQ1 and PQ11 using HPLC   
HPLC analysis of PQ1 and PQ11 was carried out on a Varian Prostar 210 with a UV-Vis 
detector. A reverse phase column from Phonomenex (250 x 21.20 mm, 10 micron, S. No: 
552581-1) was used for PQ1 analysis, whereas a C18 reverse phase column from Xper-chrom 
Aegis (S. No: 104117, 250 x 10 mm, 10 micron) was used for PQ11. For both PQ1 and PQ11, a 
flow rate of 5 mL/min and detection wavelength of 254 nm were used.  A gradient elution of 
solvent A, containing deionized water and 0.01% of trifluoroacetic acid, and solvent B, 
containing acetonitrile and 0.01% of trifluoroacetic acid, was applied for the analysis. 
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Scheme 10: Schematic representation of the regeneration of BTA from the salt of BTA with PQ 
compounds 
 
 
 
1,2,4,5-Benzenetetracarboxylic acid (BTA) was used as an internal standard to quantify 
the amount of PQ1 or PQ11 in the samples.  BTA does not undergo amide formation reaction 
with PQ compounds (amine) at ambient temperature because (i) –OH group in carboxylic acid is 
a poor leaving group and (ii) BTA has a pKa ~ 3 that is lower as compared to the pKa of the 
aminium ions of aliphatic primary amine (pKa ~ 10) and aniline (pKa ~ 4.5) resulting in a very 
small amount of free amine (nucleophile) in the equilibrium as shown in Scheme 10. Moreover, 
the presence of 0.01% of trifluoroacetic acid (pKa = 0.52) in the solvents for HPLC regenerates 
BTA from its salt as shown in Scheme 10. Solutions of 100 µL of various mixtures of authentic 
PQ1 or PQ11 and BTA were injected into an HPLC instrument, the peak areas corresponding to 
PQ1 or PQ11 and BTA were integrated from the HPLC chromatogram, and the ratios of the 
peaks were obtained. The results of the ratios of HPLC peak areas and the ratios from PQ1 or 
PQ11 and BTA concentrations were plotted, and a linear correlation line was obtained from the 
graph. Hence, using this correlation diagram, the ratio of HPLC peak areas of PQ1 or PQ11 and 
BTA from tissue extract, and the added known amount of BTA to the tissue extract, the amount 
118 
 
of PQ1 or PQ11 in the tissue or plasma extract was determined. The eluant corresponding to the 
peak that had the same retention time as that of PQ1 or PQ11 from the injection of the tissue 
extract was collected, and its mass was determined using mass spectrometer. The mass spectrum 
acquired from the collected peak of PQ1 or PQ11 from the plasma or tissue extract was identical 
to that of the authentic PQ1 or PQ11 mass spectrum. Hence, the molecular identity of PQ1 and 
PQ11 in the tissue extract was verified by mass spectrometry. An Applied Biosystem API 2000 
LS/MS/MS mass spectrometer was used in the analysis.  The eluent corresponding to PQ1 or 
PQ11 peak from the HPLC was collected and injected into the mass spectrometer.  A mass of 
406 corresponding to M+1 of PQ1 or 429 corresponding to M+1 of PQ11 was found in their 
mass spectra and the fragmentation pattern of this M+1 mass is similar to that of the authentic 
PQ1 or PQ11 verifying the identity of PQ1 and PQ11. 
The percentage distribution of PQ1 and PQ11 in the tissues was determined from the 
amount of PQ1 or PQ11 obtained in the organs compared to the total amount of the drugs 
administered to each mice. Similarly, the concentration of the drugs in the tissues was obtained 
by finding the number of moles of PQ1 or PQ11 in the given volume of the organs (mass of 
organs = volume of organs, density ~1).  
 
3.4 Results and discussions 
PQ1 and PQ11 are known to have anti-breast cancer activities in T47D cells by 
enhancing GJIC and inducing apoptosis; however, have no effect on normal human mammary 
epithelial cells (HMEC).
13,15
 It is therefore important to determine the distribution of these drugs 
in different tissues and study the toxicity of these compounds in the normal tissues. Since, the 
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studies on the effects of PQ11 on the normal tissues is ongoing, this chapter highlights the 
distribution of PQ1 and PQ11 in different tissues of normal mice and also discusses the effect of 
PQ1 in the normal tissues. Distribution of PQ1 in the mice tissues and its effect on the normal 
cells has been published recently and the results are summarized in this chapter.
18
 The effect of 
PQ1 on normal tissues was studied by Ying Ding in Dr. Annelise Nguyen laboratory.   
 
3.4.1 Tissue distribution of PQ1 
To examine the tissue distribution of PQ1 in different organs, a dose of 25mg/Kg of PQ1, 
was administered to C57BL/6J mice by oral gavage, a desirable and safe method for drugs 
administration. The main purpose of administrating higher dose of PQ1 was to evaluate the 
toxicities of PQ1 in normal tissues.   
PQ1 in the tissues was determined by plotting a calibration graph with the ratios of peak 
areas of PQ1 to BTA vs. molar ratios of PQ1 to BTA as mentioned in the experimental section of 
this chapter. The calibration graph for PQ1 is shown in Figure 23.  
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Figure 23: Correlation of ratios of peak areas of authentic BTA and PQ1 from HPLC 
chromatogram and molar ratios of PQ1 and BTA injected. Solutions of 100 µL of various 
mixtures of authentic PQ1 and BTA were injected into an HPLC, the peak areas corresponding 
to PQ1 and BTA were integrated from the HPLC chromatogram, and the ratios of the peaks were 
obtained. The results of the ratios of HPLC peak areas and the ratios from PQ1 and BTA 
concentrations were plotted, and a linear correlation line was obtained from the graph. 
 
 
The amount of PQ1 in the tissues extract was calculated by determining the peak areas 
ratio of PQ1 to BTA and determining the number of moles of PQ1 from the correlation graphs, 
as the number of moles of BTA added to the tissue extract was known. HPLC chromatograms of 
the tissues extract injected with a known amount of BTA showed a peak at 28.8 minutes which 
had the same retention time compared to the authentic PQ1 as shown in Figure 24. The 
representative mass spectrum of eluant corresponding to the peak at 28.8 min is highlighted in 
Figure 31. 
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Figure 24: Representative HPLC chromatograms of PQ1 and BTA. 24A is the HPLC 
chromatogram of 1:1 mol ratio of BTA and authentic PQ1. 24B is the HPLC chromatogram of 
the tissue extract. 24C is the HPLC chromatogram of the tissue extract with known amount of 
BTA. The peak at 28.8 min retention time in 24C had the same mass as authentic PQ1 which was 
confirmed by mass spectrometry. 
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The percentage of PQ1 distribution to the organs was calculated by defining the amount 
of PQ1 administered as 100%, and the values are highlighted in Figure 25.  
 
 
Figure 25: Percentage distribution of PQ1 in various tissues in female C57BL/6J mice in 1, 12, 
and 24 hours of PQ1 exposure. Each mouse was administered with 25 mg/Kg of PQ1 and the 
amount of PQ1 administered to each animal is defined as 100%. Data of each experiment was 
obtained from at least 3 mice and the bars are provided with (±) standard error.   
 
In one hour from the oral administration of the drug, PQ1 was detected in the major 
organs including brain, heart, lungs, liver, kidneys, and uterus. Liver and brain had the highest 
distribution of PQ1 with the respective percentage distribution of 9.2% and 4.8% of the total 
PQ1 administered to the mice. The distribution of PQ1 in the brain suggests its efficacy to 
penetrate the blood brain barrier, which is generally difficult in cases of many drugs. Uterus, 
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heart, lungs, and kidneys were found to have 2.5%, 1.2%, 1.4%, and 1 % of the total PQ1 
administered to the mice, respectively. In 12 hour time of the drug administration, the percentage 
of PQ1 distribution decreased in liver to 4.3%, brain to 2.4 %, and heart to 0.7% but increased in 
kidneys to 2.8%. This indicates the shift of drug to the kidney from where it is excreted. 
However, the amount of PQ1 in lungs and uterus remained consistent. Finally, in 24 hour time of 
the drug administration, the amount of PQ1 decreased to 3.7% in liver, 0.9% in kidney, whereas 
brain and heart had no detectable amount of PQ1 in 24 hours. The PQ1 distribution in uterus was 
found to remain consistent even in 24 hours; moreover, there was an increase of PQ1 in the lungs 
to 3% in 24 hours. These results show that PQ1 can be absorbed, distributed to major tissues, and 
metabolized in various tissues or excreted out from the body of mice.  
 For a cancer drugs to be effective, they must reach the targeted tissues in the body in 
concentrations sufficient to kill the cancer cells. Therefore, concentrations of PQ1 in the organs 
were also evaluated at 1, 12, and 24 hour times of the drug administration (Figure 26). Since the 
concentration of drugs depends on the volume of the organs, the organs having higher percentage 
of drug distribution but greater volume such as liver may have lower drug concentration 
compared to the organs which have smaller volume. PQ1 is reported to have IC50 value of 119 
nM in T47D breast cancer cells, and has shown to suppress the xenograft tumor growth of T47D 
cells in nude mice by 70% in six days with one injection of 1 µM.
13
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Figure 26: Concentration of PQ1 (µM) in various tissues in 1, 12, and 24 hours of the drug 
exposure. The concentration of PQ1 was calculated by determining the number of mmol of PQ1 
per unit volume of the organs (density of organ = 1). Each bar represents the average 
concentration of PQ1 measured in at least three mice and is provided with (±) SE. 
 
In one hour, the concentrations of PQ1 in the organs analyzed were higher than 100 µM 
with the exception of kidney which had 52 µM, values more than 50 times higher than the 
effective dosage. The highest concentration of PQ1 in the organs evaluated was 248 µM in 
uterus, followed by 217 µM in brain, 154 µM in lungs, 118 µM in heart, and 115 µM in liver. 
The concentration of PQ1 in the uterus remained consistent even after 12 and 24 hours of the 
drugs administration. In brain and heart, the concentration of PQ1 decreased to 89 µM and 68 
µM respectively in 12 hours; however, no detectable amount of PQ1 was observed in these 
organs in 24 hours. In liver, 12 hours from the drug administration, the concentration of PQ1 was 
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reduced to 54 µM and remained almost consistent till 24 hours (46 µM). The concentration of 
PQ1 in lungs and kidney was found to increase to 182 µM and 141 µM respectively in 12 hours. 
The concentration of PQ1 was found to further increase to 200 µM in the lungs in 24 hours but 
decrease in kidney to 37 µM. 
 
3.4.2 Effect of PQ1 in normal tissues 
PQ1 is known to have anti-breast cancer activity by enhancing gap junctional 
intercellular communications (GJIC) and probably inducing apoptosis.
13
 PQ1 was reported to 
inhibit 66% of T47D cells colony growth at 100 nM concentration; however, the same 
concentration had no effect on the normal human mammalian epithelial cells (HMEC), 
indicating its specificity towards cancer cells and producing no cytotoxic effect to normal cells.
13
 
Although several molecules have been reported to modulate different levels of gap junctional 
proteins and GJIC, none of these molecules have been examined in clinical trials for the 
treatment of cancers. It is therefore important to study the effect of PQ1 in normal tissues to 
evaluate its potential towards the development of anti-breast cancer drugs targeting GJIC.  
 
3.4.2.1 Effect of PQ1 on apoptosis in normal tissues 
Apoptosis is a process of programmed cell death and is important in maintaining 
homeostasis in normal cells and tissues. The balance between both pro- and anti-apoptotic 
factors is crucial in maintaining normal cell cycle in an organism. Anticancer drugs that induce 
apoptosis in healthy cells may have several adverse effects.
19
 Therefore, to understand the effect 
of PQ1 on apoptosis in normal tissues, the expressions of survivin, an anti-apoptotic protein, and 
caspases, proapoptotic proteins were evaluated in both PQ1 treated and nontreated normal 
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tissues. The expressions of caspase-8 and cleaved caspase-3 expression were evaluated for 
proapoptotic proteins. Caspase-8 is linked to have a lead role in extrinsic apoptotic pathway, 
whereas cleaved caspase-3 is a common indicator of both extrinsic and intrinsic apoptotic 
pathways.
20
 
Survivin, a member of inhibitor of apoptosis (IAP) family is linked to inhibit caspase 
activation. In one hour from the administration of PQ1, the expression of survivin was found to 
increase in all the organs, except uterus, as compared to the normal organs from the nontreated 
mice. The level of survivin increased to 14% in liver, 28% in heart, and 44% in the lungs, which 
was consistent to the concentration of PQ1 found in these organs. Survivin expression was found 
to decrease by more than 25% in the uterus. The level of survivin in brain and kidney was found 
to be consistent as compared to the control (nontreated tissues) in the first hour but increased to 
20% and 15% in 12 hours time, respectively. The expression level of survivin in nearly all 
organs was found to decrease to the same level as that of controls in 24 hours.  
Since the cleaved caspase-3 was only detected in the uterus, liver, and lungs of PQ1 
untreated animals, the expression of cleaved caspase-3 was only evaluated in these organs. In 12 
hours from the administration of PQ1, the expression level of cleaved caspase-3 significantly 
decreased by 45% in uterus, 37% in liver, and 43% in lungs. The decrease in the expression of 
cleaved caspase-3 in these organs was consistent to the concentration of PQ1 found in these 
organs. Similarly, the expression of caspase-8, a key marker of extrinsic apoptotic pathway, was 
also evaluated. In 1 hour of the PQ1 administration, all the organs showed a decrease in the 
expression of caspase-8 ranging from 12% to 37% compared to untreated organs. In 24 hours 
from the drug administration, the expression of caspase-8 was found to decrease significantly in 
the organs like heart, lungs, liver, and uterus, by 40%, 43%, 43% and 55% respectively.  
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  The increase in the expression of survivin and decrease in the expression of caspase-8 
and cleaved caspase-3 in the normal tissues suggests the role of PQ1 as the suppresser of 
apoptosis, which is in contrary to the cancer cells, where it is found to induces apoptosis. 
Therefore, PQ1 as an anticancer drug might have double advantage, one by killing cancer cells 
inducing apoptosis, and the other by suppressing apoptosis in normal cells by inhibiting pro-
apoptotic factor and activating anti-apoptotic proteins.  
 
3.4.2.2 Effect of PQ1 on connexin in normal tissues 
Connexin are gap junctional proteins. PQ1 was found to enhance GJIC by inhibiting the 
phosphorylation of Cx43.
13
 Therefore the expressions of Cx43 in the PQ1 treated and nontreated 
normal tissues were evaluated. Since Cx43 was detected in the heart, brain, and the lungs of the 
PQ1 non treated animals, the expressions of Cx43 was only studied in these organs. 
Interestingly, the expression of Cx43 was found to decrease in these organs. The expression of 
connexin was significantly lower at 24 hour time period, decreasing to 27% in brain, 69% heart, 
and 50% in lungs as compared to the controls from the PQ1 untreated animals. These studies 
indicated PQ1 to have an opposite role in normal cells as compared to the cancer cells and 
suggested that the function of PQ1 in normal cells may involve different mode of action 
compared to the previously studied in T47D cancer cells.  
 
3.4.2.3 Histological analysis of normal tissues 
The organs of PQ1 treated mice were accessed microscopically for observing histological 
changes if any had occurred to the organs. PQ1-treated liver of normal mice remained unchanged 
at 1, 12, and 24 hour times as compared to the control, indicating PQ1 produced no observable 
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toxicity to the mice. Similarly the tissues of heart, adrenal glands, kidney, and reproductive tract 
also did not show any changes as compared to the controls. Moreover, all the mice treated with 
PQ1 showed no evidence of hemorrhage or inflammatory cells.  
 
3.4.3. Tissue distribution of PQ11 
Since, the oral gavage method used to administer PQ1 in the mice had fluctuating results 
giving larger values of standard error; therefore, intraperitoneal injection of PQ11 was carried 
out to evaluate the distribution of PQ11 in different organs. A dose of 25mg/Kg (mice body 
weight) of PQ11 succinic acid salt in 100 µL of DMSO was injected to C57BL/6J mice in the 
intraperitoneal cavity. The quantification of PQ11 in the tissues was carried out as mentioned in 
the experimental section of this chapter. The ratios of HPLC peak areas of PQ11 to BTA were 
plotted vs. the ratios of number of moles of PQ11 to BTA which produced a linear correlation 
calibration plot as shown in Figure 27. Since the amount of BTA injected with the tissue extract 
is known, the calibration graph was used to determine the amount of PQ11 in the tissues. 
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Figure 27: Correlation of ratios of peak areas of authentic BTA and PQ11 from HPLC 
chromatogram and molar ratios of PQ11 and BTA injected. Solutions of 100 µL of various 
mixtures of authentic PQ11 and BTA were injected into an HPLC, the peak areas corresponding 
to PQ11 and BTA were integrated from the HPLC chromatogram, and the ratios of the peaks 
were obtained. The results of the ratios of HPLC peak areas and the ratios from PQ11 and BTA 
concentrations were plotted, and a linear correlation line was obtained from the graph. 
 
The HPLC chromatogram of the tissues extract with a known amount of BTA showed a 
peak at 9.5 minute which had the same retention time compared to the authentic PQ11 as shown 
in Figure 28. The eluant corresponding to the peak at 9.5 minute in Figure 28C had the same 
mass compared to the authentic PQ11, as confirmed by mass spectrometry. The amount of PQ11 
in the tissues extract was then calculated by determining the peak areas ratio of PQ11 to BTA 
and determining the number of moles of PQ1 from the correlation graphs, as the number of 
moles of BTA added to the tissue extract was known. The representative mass spectrum of eluant 
corresponding to the peak at 9.5 min is highlighted in Figure 32.  
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Figure 28: Representative HPLC chromatograms of PQ11 and BTA. 28A is the HPLC 
chromatogram of 1:1 mol ratio of BTA and authentic PQ11. 28B is the HPLC chromatogram of 
the tissue extract. 28C is the HPLC chromatogram of the tissue extract with known amount of 
BTA. The peak at 9.5 min retention time in 28C had the same mass as authentic PQ11 which was 
confirmed by mass spectrometry. 
 
The percentage distribution of PQ11 in plasma and various organs in the body like liver, 
brain, kidney, gastro intestine (GI), spleen, uterus, and heart was evaluated at 6, 12, 24, and 36 
hours after the administration of the compound. The percentage of PQ11 distribution in the 
organs was calculated by defining the amount of PQ11 administered as 100%. The percentage 
distribution of PQ11 in plasma and various organs in 6, 12, 24, and 36 hours are highlighted in 
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Figure 29.  Since the volume of blood recovered from the PQ11 treated varied from animal to 
animal, the percentage of drugs distribution in plasma refers to that found in 200 µL of the 
plasma analyzed. Interestingly, PQ11 was detected in all of the organs analyzed in 6 hours of the 
drug exposure. In 6 hour from the drug exposure, the percentage of drug recovered in the organs 
and plasma was 23% of the total PQ11 administrated. The highest percentage of PQ11 was found 
in liver (8.5%), followed by brain (3.3%), gastro intestinal tract (GI, 3.1%), lungs (2.2%), kidney 
(2%), uterus (1.27%), and heart (1.1%). In 200 µL of the plasma analyzed, the percentage 
distribution of PQ11 was 1.1%. From the percentage distribution of drugs in the brain, PQ11 is 
also found to penetrate the blood brain barrier and accumulate in the brain as observed in PQ1. 
Unlike PQ1, PQ11 showed better drug clearance from the organs as indicated by the 
gradual decrease of percentage drug distribution in 12, 24, and 36 hours of the drug 
administration.  In 12 hour time of the drug administration, there was no detectable amount of 
PQ11 in the spleen, and the amount of PQ11 in other organs with the exception of gastro 
intestinal tract decreased rapidly ranging from 28% to 63%. The percentage distribution of PQ11 
in gastro intestinal tract (GI) remained consistent at 6, 12, and 24 hours of the drugs 
administration but decreased significantly to 1.7 % at 36 hour time. 
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Figure 29: Percentage distribution of PQ11 in various tissues in female C57BL/6J mice in 6, 12, 
24, and 36 hours of PQ11 exposure.  Each mouse was administered with 25 mg/Kg of PQ11 and 
the amount of PQ1 administered to each animal is defined as 100%. The percentage distribution 
of PQ11 in plasma refers to that found in 200 µL of the plasma analyzed. Data of each 
experiment was obtained from 6 mice and the bars are shown with (±) standard error.   
 
The analysis showed that at 24 hours of the drugs administration, PQ11 could not be 
detected in the uterus and the heart indicating the rapid absorbance and clearance of PQ11 in 
these organs. At 24 hours from the drugs administration, GI and liver had 2.9% and 1.2% 
distribution of the drugs, whereas the percentage distributions of PQ11 in other organs were less 
than 1%. In 36 hours from the drugs administration, PQ11 was only found in GI (1.7%) and in 
liver (0.5%). The analysis showed PQ11 to have better pharmacokinetics as compared to PQ1. 
PQ11 was better absorbed, distributed, metabolized, and cleared from the body. The animals 
after 6, 12, 24, and 36 hours from the drugs administration were as active as before the 
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administration of PQ11, which indicated PQ11 to have no adverse effect to these animals. 
However, the effect of PQ11 in the normal tissues is being studied by Dr. Thu Annelise Nguyen 
and Stephanie Shishido. The preliminary studies, till to date has not indicate any toxicity effect 
to the normal cells. These data will be published in the near future. 
 PQ11 is reported to have IC50 value of 16 nM in T47D breast cancer cell, and has shown 
to suppress the xenograft tumor growth of T47D cells in nude mice by 100% in 14 days  with 
one injection of  1 µM (as per the volume of tumor) in every 2 days, in total seven injections.
13
 
In 6 hours of the drugs administration, the concentrations of PQ11 in the organs analyzed were 
more than 40 times higher than its effective dose. The highest concentration of PQ11 was found 
in heart (107 µM), followed by liver (98 µM), lungs (91µM), uterus (82 µM), brain (71 µM), 
kidneys (70%). The concentration of PQ11 in the gastro intestinal tract and spleen was 36 µM 
and 35 µM, respectively. The concentration of PQ11 decreased gradually in all the organs, with 
the exception of GI tract, with time as shown in Figure 30. The concentration of the drugs in the 
GI tract remained consistent at 6, 12, and 24 hours from the PQ11 administration, however 
decreased to 15 µM at 36 hours.  The concentration of PQ11 in the organs was greatly reduced or 
even was zeroed at 24 hours of drugs administration. And finally at 36 hours the drugs was only 
detected in liver (5.2 µM) and GI (15 µM).  
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Figure 30: Concentration of PQ11 (µM) in various tissues in 6, 12, 24, and 36 hours of the drug 
exposure. The concentration of PQ11 was calculated by determining the number of mmol of 
PQ11 per unit volume of the organs (density of organ = 1). Each bar represents the average 
concentration of PQ11 measured from 6 mice and is provided with (±) SE.  
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Figure 31: Mass spectrum of the eluant corresponding to the peak at 28.8 minutes (Figure 24C) 
which is identical to the authentic PQ1. 
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Figure 32: Mass spectrum of the eluant corresponding to the peak at 9.5 minutes (Figure 28C) 
which is identical to the authentic PQ11. 
 
 
 
 
137 
 
3.5 Conclusions 
 Substituted quinolines, PQ1 and PQ11 were distributed in the tissues following oral 
gavage and intraperitoneal injection, respectively. Both PQ1 and PQ11 were found to penetrate 
the blood brain barrier and collect in the tissues in significant amounts. These compounds were 
distributed in the tissues in the concentration that was more than 40 folds higher than their 
effective dose. The administration of PQ1 and PQ11 had no effect in the normal behavior of the 
animals indicating no short term adverse effects. PQ1 was found to increase the expression of 
survivin, an anti-apoptotic factor and decrease the expression of cleaved caspase-3 and caspase-
8, pro-apoptotic proteins. These studies indicate that PQ1 had anti-apoptotic activities in normal 
cells, in contrast to the role of PQ1 in cancer cells, where it was known to induce apoptosis. PQ1 
in normal T47D cells were found to decrease the expression of phosphorylated form of connexin 
43 (Cx43) and increase the expression of Cx43 indicating its role as GJIC enhancing agent; 
however in normal tissue PQ1 was found to have opposite role and decreased the expression of 
Cx43. This concludes that PQ1 has opposing roles in cancer and normal cells. This property 
might add advantage to PQ1 which could be used to treat cancer cells by inducing apoptosis as 
well as prevents the adverse affect of apoptosis in the normal cells. The distribution of PQ11 in 
different normal tissues indicated that it was better cleared from the tissues as compared to PQ1; 
however, its effect on normal tissues is under investigation and will be published in the near 
future.  
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Appendix A: 
1
H NMR, 
13
C NMR, and IR spectra 
Compound 22 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 14 2009
Date Stamp May 14 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-91-DPPURE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
Br
OMe
KP-4-91-DPPURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
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a
li
ze
d
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nt
en
s
ity
3.000.96
142 
 
Compound 22 
13
C NMR 
6/27/2012 3:30:36 PM
Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 13 2009 Date Stamp Jul 13 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-4-78-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 188 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent acetone Spectrum Offset (Hz) 11069.2324
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
MeO
Cl
CHO
O
Si
KP-4-78-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
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ed
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ns
ity
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Compound 23 
1
H NMR 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 15 2009 Date Stamp Aug 15 2009
File Name C:\USERS\KESHAR\KP-4-115-FR-1-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 36 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 44.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
MeO OCHO
O
Si Cl
KP-4-115-FR1-PROTON.ESP
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
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ity
6.0010.293.540.990.880.89
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Compound 23 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 16 2009 Date Stamp Jul 16 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-4-115-FR1-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 88 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
MeO
Cl
OCHO
O
Si
KP-4-115-FR1-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
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0.80
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0.90
0.95
1.00
N
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ed
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ity
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Compound 24 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 16 2009
Date Stamp Aug 16 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-117-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
MeO
O
Cl
OH
Si
KP-4-117-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
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1.00
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5.8611.693.861.000.89
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Compound 24 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep 12 2009 Date Stamp Sep 12 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-80-FR2-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 4016 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4879.6978 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
MeO
Cl
OH
O
Si
KP-4-80-FR2-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
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Compound 19 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Sep 17 2009
Date Stamp Sep 17 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-31-QUINONE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 56 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
MeO
Br
Cl
KP-5-31-QUINONE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
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0.35
0.40
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0.50
0.55
0.60
0.65
0.70
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1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.901.00
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Compound 19 
13
C NMR  
 
6/27/2012 1:52:28 PM
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  7 2009 Date Stamp Oct  7 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-119-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 9152 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.7441 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
O
MeO
Cl
Br
KP-4-119-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0.05
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Compound 19 IR 
150 
 
Compound 25 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 15 2009 Date Stamp Aug 15 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-82-FRAC1.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 24 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 54.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
MeO
O
ClSi
Br
OH
KP-4-82-FRAC1
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
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0.50
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0.60
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6.0010.273.400.910.97
 
151 
 
Compound 25 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  7 2009 Date Stamp Oct  7 2009
File Name C:\USERS\KESHAR\KP-4-115-FR2-Carbon Frequency (MHz) 100.53
Nucleus 13C Number of Transients 2112 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.9160 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OHMeO
Br
Cl
O
Si
KP-4-115-FR2-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
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Compound 2 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Oct  1 2009
Date Stamp Oct  1 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-PARADIPHENOL.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 16 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
MeO
Cl
Br
KP-5-PARADIPHENOL
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
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3.002.311.13
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Compound 2 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Oct  8 2009 Date Stamp Oct  8 2009
File Name C:\USERS\BOOK 6\KP-LI6-C13-DIPHENOL.FID\FID
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 3680 Original Points Count 18720
Points Count 32768 Pulse Sequence s2pul Receiver Gain 40.00 Solvent DMSO-d6
Spectrum Offset (Hz) 4915.7617 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT 
TEMPERATURE
OH
OH
MeO
Cl
Br
KP-LI6-C13-DIPHENOL
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
-0.10
-0.05
0
0.05
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Compound 2 IR 
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Compound 3 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Jul 19 2007
Date Stamp Jul 19 2007 File Name C:\USERS\KESHAR\KP-4-22-Proton
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent Acetone
Spectrum Offset (Hz) 999.5056 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
CHO
KP-4-22-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
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0.20
0.25
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a
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d
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en
s
ity
0.901.001.00
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Compound 3 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Aug  1 2007 Date Stamp Aug  1 2007
File Name C:\USERS\KESHAR\KP-4-22-Carbon Frequency (MHz) 50.29
Nucleus 13C Number of Transients 11897 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent Acetone Spectrum Offset (Hz) 4962.9824
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
CHOOH
OH
Cl
KP-4-22-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
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Compound 26 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Jul 20 2007
Date Stamp Jul 20 2007 File Name C:\USERS\KESHAR\DESKTOP\NMR\HUIPING\HZ-9-82-AC.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
CHOO
O
Cl
Si
Si
KP-4-25-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
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ity
6.006.0010.2410.340.880.820.88
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Compound 26 
13
C NMR 
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Aug  2 09
Date Stamp Aug  2 09 File Name C:\USERS\KESHAR\DESKTOP\KP-4-25-FRAC2\FID Frequency (MHz) 100.56
Nucleus 13C Number of Transients 96 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9502.9023 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 27.000
CHO
Cl
O
Si
O
Si
KP-4-25-FRAC2
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
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0.45
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0.55
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0.65
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Compound 27 
1
H NMR 
Acquisition Time (sec) 2.0486 Comment Std proton Date Jul 21 2007 Date Stamp Jul 21 2007
File Name C:\USERS\KESHAR\KP-5-Formate Frequency (MHz) 399.78
Nucleus 1H Number of Transients 4 Original Points Count 17199 Points Count 32768
Pulse Sequence s2pul Receiver Gain 44.00 Solvent DEUTERIUM OXIDE
Spectrum Offset (Hz) 3241.8862 Spectrum Type STANDARD Sweep Width (Hz) 8395.42 Temperature (degree C) 25.000
OCHOO
O
Cl
Si
Si
KP-5-FORMATE.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
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7.347.0812.1312.481.100.951.00
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Compound 27 
13
C NMR 
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Aug  4 09
Date Stamp Aug  4 09 File Name C:\USERS\KESHAR\DESKTOP\KP-4-FORMATE\FID Frequency (MHz) 199.9
Nucleus 13C Number of Transients 128 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9512.8496 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 25
O
Cl
OCHO
O
Si
Si
KP-4-FORMATE
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
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0.25
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Compound 28 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  2 2008
Date Stamp Aug  2 2008 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-86-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.2900 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OHO
O
Cl
Si
Si
KP-1-86-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
7.217.2513.5413.371.100.98
162 
 
Compound 28 
13
C NMR  
Acquisition Time (sec) 1.2800 Comment 13C OBSERVE Date Jan  7 2009
Date Stamp Jan  7 2009 File Name C:\USERS\KESHAR\DESKTOP\KP-4-76-SM-C13\FID Frequency (MHz) 199.9
Nucleus 13C Number of Transients 128 Original Points Count 32000 Points Count 32768
Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 9513.0752 Spectrum Type STANDARD Sweep Width (Hz) 25000.00 Temperature (degree C) 25
O
Cl
OH
O
Si
Si
KP-4-76-SM-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 29 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  6 2008
Date Stamp Aug  6 2008 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-86-DPCOLUMN.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 39.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.6563 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
Cl
OH
Br
Si
Si
KP-1-86-PROTON1.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.927.0812.3911.850.851.00
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Compound 29 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep  6 200 Date Stamp Sep  6 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-76-SM-BR\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 320 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.4648 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
Cl
OH
O
Si
Si
Br
KP-4-76-SM-BR
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
o
rm
a
li
ze
d
 I
nt
en
s
ity
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Compound 30 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Apr 21 2009
Date Stamp Apr 21 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-76-CRUDE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 100 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3816 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OMeO
O
Cl
Si
Si
Br
KP-4-76-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
6.506.549.639.483.290.97
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Compound 30 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct  8 2009 Date Stamp Oct  8 2009
File Name C:\USERS\KESHAR\KP-4-76-C13 Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1408 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.9160 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OMeO
O
Cl
Si
Si
Br
KP-4-76-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 4 
1
H NMR 
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 14 2009
Date Stamp May 14 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-91-DPPURE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 36 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
Cl
Br
OMe
KP-4-91-DPPURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.000.96
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Compound 4 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Oct 22 2009 Date Stamp Oct 22 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-91-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 17867 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.8467 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OMeOH
OH
Cl
Br
KP-4-91-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 4 IR 
 
170 
 
Compound 31 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug  4 2009
Date Stamp Aug  4 2009 File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-SM\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 18.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1003.0914 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
OH
Cl
CHO
Si
KP-4-97-SM
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
li
z
e
d
 I
n
te
n
s
it
y
7.0013.231.051.090.951.00
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Compound 31 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Aug 17 2009 Date Stamp Aug 17 2009
File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-SM-C13\FID
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 640 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.5117 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
OH
Cl
CHO
Si
KP-4-97-SM-C13
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 32 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Sep 18 2009
Date Stamp Sep 18 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-32-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 44 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3889 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
CHOO
OMe
Cl
Si
KP-5-32-DP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.1912.473.310.961.060.94
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Compound 32 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Aug 17 2009 Date Stamp Aug 17 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-SM-C13P\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 752 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4880.0840 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
CHO
Cl
O
Si
MeO
KP-4-97-SM-C13P
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 33 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 27 2007
Date Stamp Aug 27 2007 File Name C:\USERS\KESHAR\KP-4-97-Fr1-Proton
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 28.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3890 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
OCHO
Si
KP-4-97-FR1-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.1610.813.331.090.991.08
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Compound 33 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Sep  1 2009 Date Stamp Sep  1 2009
File Name C:\USERS\KESHAR\DOCUMENTS\PHD THESIS  SUPPORT JUNE 28\NMR\LACCASE\KP-4-97-FR-1-C13\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 12208 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d Spectrum Offset (Hz) 4881.2285
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
OCHO
Si
KP-4-97-FR-1-C13
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 34 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Aug 27 2009
Date Stamp Aug 27 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-FR2\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1001.6563 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
MeO
Cl
Si
OH
KP-4-97-FR2
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
5.9811.513.410.850.870.81
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Compound 34 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Aug 29 2009 Date Stamp Aug 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-4-97-FRAC2-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1856 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10557.2520 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
MeO
Cl
Si
OH
KP-4-97-FRAC2-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 35 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 26 2009 Date Stamp Aug 26 2009
File Name C:\USERS\KESHAR\KP-5-11-FR1-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 44 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 60.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
O
MeO
Cl
OH
Br
Si
KP-5-11-FR1-PROTON.ESP
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.0010.143.200.930.98
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Compound 35 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Sep  4 2009 Date Stamp Sep  4 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-5-19-SM-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 15226 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10555.8564 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
Cl
O
Si
MeO Br
KP-5-19-SM-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 5 
1
H NMR  
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 27 2009 Date Stamp Aug 27 2009
File Name C:\USERS\KESHAR\KP-5-19-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 20 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 42.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OHOH
MeO
Cl
Br
KP-5-19-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.000.89
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Compound 5 
13
C NMR  
Acquisition Time (sec) 1.3005 Comment Std proton Date Oct 23 2009 Date Stamp Oct 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\LACCASE\KP-5-19-DP-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 5696 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10554.3848 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
Cl
OH
MeO Br
KP-5-19-DP-C13
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 5 IR 
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Compound 37 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date May 19 2009
Date Stamp May 19 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 4\KP-4-95-CRUDE.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 64 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.3890 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
O
O
Cl
Br
OH
KP-4-95-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
2.442.551.1010.10
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Compound 37 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Jul  8 2009
Date Stamp Jul  8 2009 File Name E:\KESHAR NMR REMAIN\SR-10-96-PURE-13C.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 1872 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4878.5532 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
O
O
OH
Br
Cl
SR-10-96-PURE-13C
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 6 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jul  7 2009 Date Stamp Jul  7 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-5-13-CRUDE\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 4 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 46.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.9280 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OHOH
OH
Cl
Br
KP-5-13-CRUDE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
0.820.890.850.89
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Compound 6 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Jul 22 2009 Date Stamp Jul 22 2009
File Name E:\KESHAR NMR REMAIN\SR-10-97-REPEAT-C13-METHANOL-D4.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 7048 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent METHANOL-d4 Spectrum Offset (Hz) 4978.7695
Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
OH
OH
Br
Cl
SR-10-97-REPEAT-C13-METHANOL-D4
220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
0
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.009
0.010
0.011
0.012
0.013
0.014
0.015
0.016
N
o
rm
a
liz
e
d
 I
nt
en
s
ity
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Compound 6 IR 
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Compound 7 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jun  2 2008 Date Stamp Jun  2 2008
File Name C:\USERS\KESHAR\DESKTOP\NMR\OTHERS\KP-1-16-FRAC-13-29.FID\FID Frequency (MHz) 399.76
Nucleus 1H Number of Transients 32 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 50.00 Solvent DEUTERIUM OXIDE
Spectrum Offset (Hz) 2455.7793 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
CH2OH
OH
NH2
KP-1-16-FRAC-13-29
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 In
te
ns
ity
2.081.031.010.89
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Acquisition Time (sec) 1.3005 Comment Std proton Date Jul 17 2009 Date Stamp Jul 17 2009
File Name C:\USERS\KESHAR\KP-1-16-FR2-C13\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 26396 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent DMSO-d6 Spectrum Offset (Hz) 10486.7480
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
CH2OH
OH
NH2
KP-1-16-FR2-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
Compound 7 
13
C NMR 
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Compound 7 IR 
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Compound 8 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Jun  2 2008 Date Stamp Jun  2 2008
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 1\KP-1-16-FRAC-4-9.FID\FID Frequency (MHz) 399.76
Nucleus 1H Number of Transients 32 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 56.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2418.0771 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
CH3 NH2
OH
KP-1-16-FRAC-4-9
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
3.261.000.921.07
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Compound 8 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std Carbon experiment Date Jun 28 2012
Date Stamp Jun 28 2012 File Name C:\USERS\KESHAR\DESKTOP\KP-1-16-FRAC1-C13.FID\FID
Frequency (MHz) 100.58 Nucleus 13C Number of Transients 1664 Original Points Count 31413
Points Count 32768 Pulse Sequence s2pul Receiver Gain 20.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10556.1475 Spectrum Type STANDARD Sweep Width (Hz) 24154.59 Temperature (degree C) 25.000
CH3
NH2
OH
KP-1-16-FRAC1-C13
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 8 IR 
 
 
194 
 
Compound 9 
1
H NMR  
 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Nov 16 2009
Date Stamp Nov 16 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-72-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 32 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 34.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.0226 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
KP-5-72-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
or
m
al
iz
ed
 In
te
ns
ity
6.5018.030.850.821.86
195 
 
Compound 9 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE
KP-5-72-Dp-C13 Date Nov 18 2009
Date Stamp Nov 18 2009 File Name C:\USERS\KESHAR\KP-5-72-Carbon
Frequency (MHz) 50.29 Nucleus 13C Number of Transients 384 Original Points Count 18720
Points Count 32768 Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4878.5537 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
KP-5-72-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
 
 
196 
 
Compound 10 
1
H NMR 
Acquisition Time (sec) 1.9945 Comment STANDARD 1H OBSERVE Date Nov 17 2009
Date Stamp Nov 17 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-73-DP.FID\FID
Frequency (MHz) 199.98 Nucleus 1H Number of Transients 96 Original Points Count 5984
Points Count 8192 Pulse Sequence s2pul Receiver Gain 18.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 1002.7551 Spectrum Type STANDARD Sweep Width (Hz) 3000.30 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
Br
KP-5-73-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
18.306.320.992.00
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Compound 10 
13
C NMR 
Acquisition Time (sec) 1.4976 Comment 13C OBSERVE Date Nov 18 2009 Date Stamp Nov 18 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-73-DP-C13.FID\FID Frequency (MHz) 50.29
Nucleus 13C Number of Transients 416 Original Points Count 18720 Points Count 32768
Pulse Sequence s2pul Receiver Gain 40.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 4879.3164 Spectrum Type STANDARD Sweep Width (Hz) 12500.00 Temperature (degree C) AMBIENT TEMPERATURE
OH
O
Br
KP-5-73-CARBON.ESP
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 11 
1
H NMR  
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-77-CRUDE.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 8 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 48.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2404.7087 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
OH
KP-5-77-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
6.0717.362.131.142.00
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Compound 11 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-77-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 512 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10550.8555 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
OH
KP-5-77-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 12 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 24 2009 Date Stamp Nov 24 2009
File Name C:\USERS\KESHAR\DESKTOP\KESHAR NEW NMR BACKUP 2011\NMR BACK UP 4 AND 5\KP-5-78-DP.FID\FID
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 4 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 36.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2405.0991 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
O
H
KP-5-78-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
24.000.941.920.83
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Compound 12 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 24 2009 Date Stamp Nov 24 2009
File Name C:\USERS\KESHAR\DOCUMENTS\KESHAR NMR\KESHAR\COPY OF KESHAR NOVA 3-16-2011\KESHAR\KP-5-78-C13.FID\FID
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 448 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
O
H
KP-5-78-CARBON.ESP
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 12 IR 
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Compound 14 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\KP-5-69-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 16 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2405.0991 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
N
H
OH
KP-5-69-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
19.186.451.052.170.990.95
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Compound 14 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\KP-5-69-Carbon
Frequency (MHz) 100.53 Nucleus 13C Number of Transients 544 Original Points Count 31375
Points Count 32768 Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
N
H
OH
KP-5-69-CARBON.ESP
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
-0.05
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 14 IR 
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Compound 15 
1
H NMR  
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 29 2009 Date Stamp Nov 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-81-FRAC2.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 20 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2454.6799 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
NH
KP-5-81-FRAC2
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
o
rm
a
li
ze
d
 I
nt
en
s
ity
7.0019.202.142.121.085.21
207 
 
Compound 15 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 29 2009 Date Stamp Nov 29 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-81-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 1000 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10550.1191 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
NH
KP-5-81-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 16 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-42-FRAC2-PURE.FID\FID Frequency (MHz) 399.75
Nucleus 1H Number of Transients 16 Original Points Count 13103 Points Count 16384
Pulse Sequence s2pul Receiver Gain 32.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2403.5376 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
KP-5-42-FRAC2-PURE
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
9.769.493.002.871.980.910.970.900.93
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Compound 16 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 23 2009 Date Stamp Nov 23 2009
File Name E:\KESHAR NMR REMAIN\KP-5-42-FRAC2.FID\FID Frequency (MHz) 100.53 Nucleus 13C
Number of Transients 512 Original Points Count 31375 Points Count 32768 Pulse Sequence s2pul
Receiver Gain 30.00 Solvent CHLOROFORM-d Spectrum Offset (Hz) 10550.8555
Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
OH
KP-5-42-FRAC2
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
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Compound 17 
1
H NMR 
Acquisition Time (sec) 2.0487 Comment KP-5-85-frac19 Date Dec  3 2009
Date Stamp Dec  3 2009 File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-85-FRAC19.FID\FID
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 28 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 42.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2404.7219 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
O
KP-5-85-FRAC19
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0 -0.5
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
9.006.089.122.032.030.910.97
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Compound 17 
13
C NMR 
Acquisition Time (sec) 1.3005 Comment Std proton Date Nov 25 2009 Date Stamp Nov 25 2009
File Name C:\USERS\KESHAR\DESKTOP\NMR\BOOK 5\KP-5-76-FRAC7-C13.FID\FID Frequency (MHz) 100.53
Nucleus 13C Number of Transients 512 Original Points Count 31375 Points Count 32768
Pulse Sequence s2pul Receiver Gain 30.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 10551.5918 Spectrum Type STANDARD Sweep Width (Hz) 24125.45 Temperature (degree C) 25.000
O
KP-5-76-FRAC7-C13
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
o
rm
a
liz
e
d
 I
nt
en
s
ity
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MON-0585 (compound 18) 
1
H NMR  
Acquisition Time (sec) 2.0487 Comment Std proton Date Aug 24 2009 Date Stamp Aug 24 2009
File Name C:\USERS\KESHAR\KP-5-15-Proton
Frequency (MHz) 399.75 Nucleus 1H Number of Transients 40 Original Points Count 13103
Points Count 16384 Pulse Sequence s2pul Receiver Gain 36.00 Solvent CHLOROFORM-d
Spectrum Offset (Hz) 2397.2451 Spectrum Type STANDARD Sweep Width (Hz) 6395.91 Temperature (degree C) 25.000
OH
KP-5-15-FRAC1-PROTON.ESP
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
N
or
m
al
iz
ed
 In
te
ns
ity
18.006.310.961.904.09
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Appendix B: Permission for figures 
1. Permission for Figure 2 
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2. Permission for Figure 3 
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3. Permission for Figure 6 and 7 
 
 
